US20130266584A1 - Methods and compositions for treating celiac disease - Google Patents
Methods and compositions for treating celiac disease Download PDFInfo
- Publication number
- US20130266584A1 US20130266584A1 US13/695,349 US201113695349A US2013266584A1 US 20130266584 A1 US20130266584 A1 US 20130266584A1 US 201113695349 A US201113695349 A US 201113695349A US 2013266584 A1 US2013266584 A1 US 2013266584A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- pharmaceutical composition
- aai
- gliadin
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 33
- 208000015943 Coeliac disease Diseases 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 239000003392 amylase inhibitor Substances 0.000 claims abstract description 20
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 12
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 claims abstract description 7
- 101710114259 Alpha-amylase inhibitor 0.53 Proteins 0.000 claims abstract description 6
- 101710113918 Alpha-amylase inhibitor 0.19 Proteins 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 10
- 235000021277 colostrum Nutrition 0.000 claims description 8
- 210000003022 colostrum Anatomy 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 208000010643 digestive system disease Diseases 0.000 claims description 7
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract description 29
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract description 29
- 230000015788 innate immune response Effects 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 17
- 238000003556 assay Methods 0.000 abstract description 15
- 230000003472 neutralizing effect Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 239000003112 inhibitor Substances 0.000 abstract description 7
- -1 0.19 Proteins 0.000 abstract description 6
- 230000001960 triggered effect Effects 0.000 abstract description 6
- 108010061711 Gliadin Proteins 0.000 description 77
- 210000004027 cell Anatomy 0.000 description 65
- 108090000765 processed proteins & peptides Proteins 0.000 description 61
- 102000004196 processed proteins & peptides Human genes 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 45
- 239000002158 endotoxin Substances 0.000 description 44
- 102000004890 Interleukin-8 Human genes 0.000 description 40
- 108090001007 Interleukin-8 Proteins 0.000 description 40
- 230000028327 secretion Effects 0.000 description 34
- 229920001184 polypeptide Polymers 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 31
- 101710162629 Trypsin inhibitor Proteins 0.000 description 29
- 101710112753 A-type inclusion protein A25 homolog Proteins 0.000 description 28
- 210000002383 alveolar type I cell Anatomy 0.000 description 28
- 210000004443 dendritic cell Anatomy 0.000 description 24
- 230000000638 stimulation Effects 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 22
- 210000001616 monocyte Anatomy 0.000 description 22
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 19
- 241000209140 Triticum Species 0.000 description 19
- 235000021307 Triticum Nutrition 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 17
- 229920002494 Zein Polymers 0.000 description 17
- 239000005019 zein Substances 0.000 description 17
- 229940093612 zein Drugs 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 15
- 238000001262 western blot Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 239000000556 agonist Substances 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 10
- 240000005979 Hordeum vulgare Species 0.000 description 10
- 235000007340 Hordeum vulgare Nutrition 0.000 description 10
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 10
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 9
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 210000003024 peritoneal macrophage Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 108700042314 Triticum aestivum WDAI-3 Proteins 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 235000006171 gluten free diet Nutrition 0.000 description 7
- 235000020884 gluten-free diet Nutrition 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 101710172128 Alpha-amylase/trypsin inhibitor Proteins 0.000 description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 6
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 description 6
- 108010067770 Endopeptidase K Proteins 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 108010068370 Glutens Proteins 0.000 description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 6
- 108091030071 RNAI Proteins 0.000 description 6
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- 230000002183 duodenal effect Effects 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- HZWWPUTXBJEENE-UHFFFAOYSA-N 5-amino-2-[[1-[5-amino-2-[[1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CCC(C(=O)NC(CCC(N)=O)C(=O)N2C(CCC2)C(=O)NC(CCC(N)=O)C(O)=O)N1C(=O)C(N)CC1=CC=C(O)C=C1 HZWWPUTXBJEENE-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 244000098338 Triticum aestivum Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 235000021312 gluten Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- 230000010777 Disulfide Reduction Effects 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000007578 Interferon Regulatory Factor-3 Human genes 0.000 description 4
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 101710087459 Gamma-gliadin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241001522110 Aegilops tauschii Species 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 2
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000209056 Secale Species 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 108010050792 glutenin Proteins 0.000 description 2
- 235000011868 grain product Nutrition 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 230000028604 virus induced gene silencing Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical group C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 101710161606 Alpha-amylase/trypsin inhibitor CM16 Proteins 0.000 description 1
- 101710105555 Alpha-amylase/trypsin inhibitor CM3 Proteins 0.000 description 1
- 101710204137 Alpha-amylase/trypsin inhibitor CMb Proteins 0.000 description 1
- 101710204138 Alpha-amylase/trypsin inhibitor CMd Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000724306 Barley stripe mosaic virus Species 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 101710183587 Omega-gliadin Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 208000021329 Refractory celiac disease Diseases 0.000 description 1
- 102100035729 Replication protein A 70 kDa DNA-binding subunit Human genes 0.000 description 1
- 241000191025 Rhodobacter Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 101150082427 Tlr4 gene Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940092523 bartonella quintana Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- KVJWZTLXIROHIL-QDORLFPLSA-N lipid IVA Chemical compound O[C@H]1[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@H](OP(O)(O)=O)[C@@H](CO)O1 KVJWZTLXIROHIL-QDORLFPLSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000020790 strict gluten-free diet Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8245—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
Definitions
- This invention relates to the treatment of celiac disease with compounds that decrease inflammation resulting from contact with wheat alpha Amylase inhibitors, including CM3 or 0.19.
- CD Celiac disease
- CD patients can develop serious secondary morbidity, such as T cell lymphoma and autoimmune diseases.
- the disorder is considered to be the result of a complex interplay of intrinsic (genetic) and variable extrinsic (environmental) factors that explain the wide spectrum of clinical manifestations ranging from asymptomatic to severe malabsorption.
- Tissue transglutaminase which has been identified as the highly specific endomysial autoantigen, is increasingly released from cells during inflammation. It usually potentiates antigen presentation by HLA-DQ2 and HLA-DQ8 by deamidating and cross-linking gluten peptides. The result is lamina intestinal T-cell activation and mucosal transformation by activated intestinal mononuclear cells and fibroblasts.
- celiac disease is typically treated with a strict gluten free diet.
- a gluten free diet is difficult to maintain and non-dietary treatment alternatives are urgently needed.
- even a gluten free diet may not lead to remission in patients with refractory celiac disease.
- the invention features a pharmaceutical composition including an antibody (e.g., a polyclonal, monoclonal, or humanized antibody) against alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, alpha amylase inhibitor 0.53 (0.53), and structurally and functionally related molecules (collectively termed AAI).
- the antibody can be formulated for, e.g., oral administration (e.g., in milk or colostrum).
- the antibody can be produced in the milk or colostrum of a mammal (e.g., goat or cow).
- the antibody can be formulated to be active in the intestine.
- the invention features a method of treating a gastrointestinal disorder (e.g., celiac disease, ulcerative colitis, Crohn's disease, or irritable bowel syndrome) by administering any of the pharmaceutical compositions described above or an oral or systemic TLR4 inhibitor (e.g., as described below).
- a gastrointestinal disorder e.g., celiac disease, ulcerative colitis, Crohn's disease, or irritable bowel syndrome
- the pharmaceutical composition can be administered immediately prior to, during or after a meal, or can be administered, e.g., once, twice, or three times daily.
- the invention features a method of determining a substance's potency in inducing a negative gastrointestinal reaction by measuring the AAI content of the substance, where the measurement is indicative of the potency of the substance in inducing a negative gastrointestinal reaction.
- This method can include dispersing all or a fraction of the substance in an aqueous solution, contacting the solution with an antibody specific for an AAI (e.g., an antibody bound to a substrate) under conditions conducive to specific binding, and measuring the amount of the antibody bound to the AAI.
- this method features an ELISA assay.
- the invention features a method of testing the sensitivity of a subject to ingestion of AAI containing substances by measuring the levels (e.g., with an ELISA assay) of anti-AAI antibody in sample isolated from the subject (e.g., a blood or stool sample) where the levels are indicative of the sensitivity of the subject to ingestion of AAI containing substances.
- levels e.g., with an ELISA assay
- sample isolated from the subject e.g., a blood or stool sample
- the invention features a method of reducing the potency of a substance in inducing a negative gastrointestinal reaction by reducing the AAI content of the substance (e.g., through enzymatic degradation, disulfide reduction, or separation of AAI).
- the invention features a cereal product (e.g., wheat, rye, barley, oats, corn or rice) including reduced levels of AAI protein (e.g., through enzymatic degradation, disulfide reduction, separation, or by derivation from cereals engineered to express AAI at decreased levels) compared to levels of AAI in naturally occurring cereal products.
- a cereal product e.g., wheat, rye, barley, oats, corn or rice
- AAI protein e.g., through enzymatic degradation, disulfide reduction, separation, or by derivation from cereals engineered to express AAI at decreased levels
- the invention features a nucleic acid construct encoding an RNAi molecule against AAI and a vector including a nucleic acid construct encoding an RNAi molecule against AAI.
- the invention also features a transgenic plant including any of the above nucleic acid constructs or vectors. These transgenic plants can be processed into food products with decreased AAI content thereby resulting in less potent induction of a negative gastrointestinal reaction in a subject with a gastrointestinal disorder (e.g., celiac disease, ulcerative colitis, and Crohn's disease).
- a gastrointestinal disorder e.g., celiac disease, ulcerative colitis, and Crohn's disease.
- CM3 CM3 and 0.19
- CM3 any polypeptide having the activity of full-length CM3 or 0.19 protein:
- CM3 (SEQ ID NO: 1) MACKSSCSLLLLAAVLLSVLAAASASGSCVPGVAFRTNLLPHCRDYVL QQTCGTFTPGSLPEWMTSASIYSPGKPYLAKLYCCQELAEISQQCRCEA LRYFIALPVPSQPVDPRSGNVGESGLIDLPGCPREMQWDFVRLLVAPGQ CNLATIHNVRYCPAVEQPLWIDYKDDDDK.
- CM3 wheat alpha Amylase inhibitor
- CM3 wheat alpha Amylase inhibitor 0.19
- 0.19 also are used herein to refer to CM3 or 0.19 fragments, which may be, e.g., functional, antigenic, and/or immunogenic. Further, these terms also encompass CM3 or 0.19 polypeptides or fragments including additional terminal amino acids, e.g., an amino terminal methionine.
- CM3 protein binding to TLR4 and induction of IL-8 secretion in monocytes, macrophages, or dendridic cells as described herein.
- wheat alpha Amylase inhibitor CM3 proteins or peptides having at least 20%, e.g., at least 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) amino acid sequence identity to the sequence of SEQ ID NO:1 or SEQ ID NO:2. Proteins having such amino acid sequence identity can, e.g., have cysteine residues at positions corresponding to the amino acid residue located in the CM3 protein at residue numbers 29, 43, 83, 84, 94, 96, 130, and 159.
- CM1 CM2
- CMa CMd
- CM16 CMb
- CMX1/CMX3 CMX2
- alpha amylase inhibitor 0.53 0.53
- CM1, CM2, CMa 5 CMd
- CM16 CM16
- CMb CMX1/CMX3
- CMX2 alpha amylase inhibitor 0.53
- CM1 proteins or peptides having at least 20%, e.g., at least 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) amino acid sequence identity to the sequence of SEQ ID NOs: 6-11, respectively having the activity of binding to TLR4 and induction of IL-8 secretion in monocytes, macrophages, or dendridic cells as described herein. Proteins having such amino acid sequence identity can, e.g., have cysteine residues at positions corresponding to the amino acid residue located in the CM3 protein at residue numbers 29, 43, 83, 84, 94, 96, 130, and 159.
- polypeptide By “polypeptide,” “polypeptide fragment,” or “peptide” is meant a chain of two or more (e.g., 10, 15, 20, 30, 50, 100, or 175, or more) amino acids, regardless of any post-translational modification (e.g., glycosylation or phosphorylation), constituting all or part of a naturally or non-naturally occurring polypeptide, fragment, or peptide.
- post-translational modification is meant any change to a polypeptide or polypeptide fragment made during or after synthesis. Post-translational modifications can be produced naturally (such as during synthesis within a cell) or generated artificially (such as by recombinant or chemical means).
- a “protein” can be made up of one or more polypeptides.
- identity is used herein to describe the relationship of the sequence of a particular nucleic acid molecule or polypeptide (or a fragment thereof) to the sequence of a reference molecule of the same type (or a fragment thereof). For example, if a nucleic acid or amino acid molecule has the same nucleotide or amino acid residue at a given position, as compared to a reference molecule to which it is aligned, there is said to be “identity” at that position.
- sequence identity of a nucleic acid molecule or a polypeptide to a reference molecule is typically measured using sequence analysis software with the default parameters specified therein, such as the introduction of gaps to achieve an optimal alignment (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, or PILEUP/PRETTYBOX programs). These software programs match identical or similar sequences by assigning degrees of identity to various substitutions, deletions, or other modifications.
- sequence of a nucleic acid molecule or polypeptide is said to be “substantially identical” to that of a reference molecule if it exhibits, over its entire length, at least 51%, e.g., at least 55%, 60%, 65%, 75%, 85%, 90%, or 95% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the sequence of the reference molecule.
- the length of comparison sequences may be, for example, at least 10, 15, 20, 30, 50, 100, or 175, or more amino acids.
- a molecule e.g., an oligonucleotide probe or primer, a gene or fragment thereof, a cDNA molecule, a polypeptide, or an antibody
- detectably labeling molecules include, without limitation, radioactive labeling (e.g., with an isotope, such as 32 P or 35 S) and nonradioactive labeling (e.g., with a fluorescent label, such as fluorescein).
- a “substantially pure” polypeptide e.g., antibody
- a polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally occurring organic molecules with which it is naturally associated.
- the polypeptide can be a polypeptide that is at least 75%, 90%, or 99%, by weight, pure.
- a substantially pure polypeptide can be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid molecule encoding a polypeptide, or by chemical synthesis. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- a polypeptide is substantially free of naturally associated components when it is separated from those proteins and organic molecules that accompany it in its natural state.
- a protein that is chemically synthesized or produced in a cellular system that is different from the cell in which it is naturally produced is substantially free from its naturally associated components.
- substantially pure polypeptides not only include those that are derived from eukaryotic organisms, but also those synthesized in E. coli, other prokaryotes, or in other such systems.
- An antibody is said to “specifically bind” to a polypeptide or fragment if it recognizes and binds to the polypeptide (e.g., CM3 or 0.19), but does not substantially recognize and bind to other molecules (e.g., non-CM3- or non-0.19-related polypeptides) in a sample, e.g., a biological sample that includes the polypeptide.
- a polypeptide or fragment e.g., CM3 or 0.19
- other molecules e.g., non-CM3- or non-0.19-related polypeptides
- Neutralizing antibodies would, for example, block stimulation of monocytes or dendridic cells by AAI (e.g., CM3 and/or 0.19) in the assays described herein (e.g., by decreasing secretion of IL-8 by 70%, 80%, 90%, 95%, 99%, or greater compared to control).
- AAI e.g., CM3 and/or 0.19
- TLR4 e.g., by decreasing binding by 70%, 80%, 90%, 95%, 99%, or greater compared to control.
- sample is meant a tissue biopsy, amniotic fluid, cell, blood, serum, urine, stool, or other specimen obtained from a patient or a test subject.
- AAI e.g., CM3 and 0.19
- PCR or RT/PCR can be used to measure the level of AAI (e.g., CM3 and 0.19) nucleic acid molecules.
- negative gastrointestinal reaction an innate immune response triggered by AAI (e.g., CM3 and/or 0.19) that results in undesirable symptoms (e.g., those associated with celiac disease).
- AAI e.g., CM3 and/or 0.19
- potency is meant the degree to which a substance induces an innate immune response against AAI protein (e.g., CM3 and/or 0.19 protein).
- treating is meant administering a pharmaceutical composition for prophylactic and/or therapeutic purposes or administering treatment to a subject already suffering from a disease to improve the subject's condition or to a subject who is at risk of developing a disease.
- treating can include improving or ameliorating the symptoms of an undesired immune response triggered by AAI (e.g., CM3 and/or 0.19), and prophylactic treatment can include preventing the progression of a mild gastrointestinal disorder to a more serious form. Treating may also mean to prevent the onset of an negative gastrointestinal reaction.
- AAI e.g., CM3 and/or 0.19
- FIGS. 1A-1D are a series of graphs showing IL-8, TNF- ⁇ , and MCP-1 release in cells treated with the indicated compounds.
- the experiments of FIGS. 1A and 1C were conducted in monocytic THP-1 cells and the experiments of FIGS. 1B and 1D were conducted in monocytic U937 cells.
- FIG. 1E is a graph showing expression of IL-8 in HT29 (intestinal epithelial), U937, and THP-1 cells treated with alpha-gliadin peptide p31-43 and a scrambled control peptide.
- FIG. 1F is a graph showing expression of IL-8 in THP-1 cells treated with the indicated compounds and treated and untreated with proteinase K.
- FIG. 2A is a graph showing IL-8 expression in monocyte derived dendritic cells of healthy control patients or of celiac disease patients on the indicated diet treated with the indicated compound.
- FIG. 2B is a graph showing IL-8 expression of monocyte derived dendritic cells from a healthy control in response to various doses of pepsin/trypsin digested (PT) gliadin. Stimulation with LPS and PT zein served as positive and negative controls, respectively.
- PT pepsin/trypsin digested
- FIG. 2C is a series of graphs showing a flow cytometric analysis of dendritic cells of healthy controls stimulated with PT gliadin. Upregulation of dendritic cell surface maturation markers can be observed in the grey filled and the dotted histogram that represent PT gliadin and LPS stimulation, respectively, whereas PT zein stimulation (non filled) overlaps with the non stimulated control.
- FIGS. 3A and 3B are graphs showing KC (rodent IL-8) and TNF- ⁇ expression in peritoneal macrophages isolated from TLR4 deficient C3H/HeJ mice compared to C3H/HOuJ wildtype mice stimulated with LPS or PT gliadin.
- the TLR2 agonist Pam3CSK4 served as positive control.
- FIGS. 3C and 3D are graphs showing expression of IL-8 secretion upon PT gliadin and LPS stimulation in 293 cells transfected with the TLR4-MD2-CD14 complex ( 3 D) and in non transfected cells ( 3 C). LPS and PMA served as positive, the TLR2 agonist Pam3CSK4 as negative controls.
- FIG. 3E is a graph showing IL-8 secretion in monocyte derived dendridic cells stimulated with PT gliadin and LPS with peritoneal macrophages preincubated with anti-TLR4 and anti-CD14 antibodies.
- TLR2 agonist Pam3CSK4 and TLR3 agonist Poly I:C served as positive controls.
- FIG. 4A is a graph showing TNF-alpha secretion in peritoneal macrophages isolated from MyD88 ⁇ / ⁇ mice compared to C57BL/6 wildtype mice upon PT gliadin stimulation.
- LPS served as positive control for the MyD88 knockdown
- TLR3 agonist Poly I:C served as cell viability control.
- FIG. 4B is a graph showing RANTES secretion in peritoneal macrophages isolated from C57BL/6J mice upon LPS, Poly I:C and PT gliadin stimulation.
- FIG. 4C is a graph showing stimulation of THP-1 cells with ⁇ -, ⁇ -, ⁇ 1.2 and ⁇ 5-gliadin fractions isolated from the pure wheat strain ‘Rektor’. Co-incubation of ⁇ - and ⁇ -gliadin with regular PT gliadin from Sigma served as cell viability control.
- FIGS. 4D and 4E are graphs showing IL-8 secretion in TLR4 transfected ( 4 D) and untransfected ( 4 E) HEK-293 cells treated with ⁇ -gliadins.
- FIG. 4F is a graph showing IL-8 secretion in TLR4 transfected HEK-293 cells treated with synthetic overlapping 20 mers of co5-gliadin. For illustration purposes, nine fractions each were pooled in the stimulation experiments, as well as all 43 fractions. LPS served as positive and Pam3CSK4 or PT zein as negative controls.
- FIGS. 5A and 5B are graphs showing KC expression by monocyte derived dendritic cells stimulated with water-soluble (ws) gliadin ( 5 A) or alpha amylase trypsin inhibitor (ATI, 5 B).
- ws water-soluble
- ATI alpha amylase trypsin inhibitor
- FIG. 5C is a graph showing IL-8 secretion in dendritic cells treated with a proteinase K digestion of ATI and LPS.
- FIG. 5D is a graph showing KC secretion in peritoneal macrophages isolated from MyD88 ⁇ / ⁇ mice compared to C57BL/6J wildtype mice upon ATI or ws gliadin stimulation.
- FIGS. 5E and 5F are graphs showing IL-8 secretion upon PT gliadin, ATI, or LPS stimulation in 293 cells transfected with the TLR4-MD2-CD14 complex ( 5 E) and in non transfected cells ( 5 F). LPS and water-soluble zein served as positive and negative controls, respectively.
- FIG. 6A is a graph showing IL-8 secretion in monocyte derived dendritic cells stimulated with ATI and LPS and preincubated with anti-TLR4 or anti-CD14 antibodies.
- TLR2 agonist Pam3CSK4 served as positive control.
- FIG. 7A is a western blot showing the major ATI variant CM3 was expressed in eukaryotic 293 cells and purified as Flag-tagged molecule, yielding the expected molecular weights of 16 kD.
- FIG. 7B is a graph showing IL-8 secretion in human dendritic cells upon stimulation with ATI and the recombinant CM3 variant.
- FIG. 7C is a western blot showing expression of NF- ⁇ B and the alternative (IRF3) pathways in CM3 and TLR4-transfected HEK cells.
- FIG. 7D is a photomicrograph showing apoptosis in TLR4- and CM3-transfected and untransfected HEK cells.
- FIGS. 8A-8C are supplementary graphs showing expression of IL-8 ( 8 A), TNF- ⁇ ( 8 B), and RANTES ( 8 C) in gliadin stimulated human monocyte derived DC from healthy controls.
- FIG. 9A is a western blot showing CM3 and 0.19 expression in HEK-293 cells and purification as Flag-tagged molecules.
- Western analysis yielded the expected molecular weights of 15 and 17 kDa, respectively, after 15% SDS-PAGE and Western blotting with Flag antibody.
- FIG. 9B is a Coomassie blue stain (left panel) or western blot using Flag antibody (right panel) showing purity of CM3 and 0.19 ATI after affinity purification on Flag-agarose (15% SDS-PAGE).
- FIG. 9C is a graph showing IL-8 secretion by TLR4-CD14-MD2 expressing HEK-293 cells treated with recombinant ATI.
- Cells were left untreated, or stimulated with affinity purified detergent extracts from mock-transfected cells, from recombinant CM3, 0.19, or with ATI isolated from wheat (all 5 ⁇ g/ml).
- Controls were Flag peptide (5 ⁇ g/ml), PT-gliadin (100 ⁇ g/ml), and LPS (10 ng/ml). Representative experiment performed in triplicate.
- FIG. 9D is a western blot showing expression of CM3 and 0.19 in TLR4-CD14-MD2 expressing HEK-293 cells (HEK-TLR4) induces downstream signaling of the canonical (p-NF- ⁇ B/p65) and the alternative (p-IRF3) pathways.
- FIGS. 10A and 10B are a sequence alignments.
- FIG. 10A shows an alignment between CM3 and 0.19.
- FIG. 10B shows an alignment between CM3 or 0.19 and other ATIs from wheat and barley (CMa, CMb, CMd) (SEQ ID NOs, in order listed are SEQ ID NOs:: 3-5, 1, 6-10, 2, and 11).
- the sequence alignment was prepared using the ClustalW program (2.0.12 version).
- the highly conserved cysteine residues are boxed.
- (*), (:), and (.) denote identity, high homology, and low homology, of amino acid residues, respectively. Similarities are much higher among individual ATIs.
- the invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, alpha Amylase Inhibitor 0.53 (0.53) (collectively termed AAI), and other structurally and functionally related molecules.
- alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 0.19
- CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, alpha Amylase Inhibitor 0.53 (0.53) (collectively termed AAI), and other structurally and functionally related molecules.
- the invention provides pharmaceutical compositions including neutralizing antibodies to alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, alpha Amylase Inhibitor 0.53 (0.53), and other structurally and functionally related molecules, food products containing reduced levels of AAI proteins, assays for identifying AAI protein content in food products, and assays for diagnosing subjects with a disorder related to AAI-triggered innate immune responses.
- the invention also features methods of treating gastrointestinal disorders associated with an innate immune response to these molecules with preferably, but not exclusively orally active TLR4 inhibitors.
- CM3 and/or 0.19 contributes to the activation of innate immunity in patients with celiac disease.
- An exemplary wheat CM3 protein has the sequence of
- An exemplary wheat 0.19 protein has the sequence of:
- the invention provides methods for the treatment of negative gastrointestinal reactions to other cereal-based (e.g., barley, rye, oats, corn, and rice) CM3 or 0.19 proteins, or related molecules, e.g., those set forth in Tables 1 and 2.
- cereal-based e.g., barley, rye, oats, corn, and rice
- CM3 or 0.19 proteins, or related molecules e.g., those set forth in Tables 1 and 2.
- TLR4 inhibitors for pharmaceutical use are known in the art.
- Such inhibitors include synthetic gluco-disaccharides such as RSCL-0409 (Kalluri et al. FEBS J. 2010 April; 277(7):1639-52); TLR4 (MD2-TLR4) blocking antibodies (Ungaro et al. Am J Physiol Gastrointest Liver Physiol. 2009 June; 296(6):G1167-79); phosphatidyl-ethanolamine (Lee et al. Mol Cells. 2009 Feb. 28; 27(2):251-5); peptide antagonists (Slivka et al. Chembiochem. 2009 Mar.
- LPS variants such as LPS from cyanobacteria, Rhodobacter capsulates, Porphyromonas gingivalis and Capnocytophagatochracea or Helicobacter pylori (Ianaro et al. Mini Rev Med Chem. 2009 Mar; 9(3):306-17; Jemmett et al. Infect Immun. 2008 July; 76(7):3156-63; and Macagno A, et al. J Exp Med. 2006 Jun. 12; 203(6):1481-92), Bartonella Quintana (Popa et al. Infect Immun 2007 October; 75(10):4831-7), Treponema (Lee et al.
- any of the agents employed according to the present invention may be contained in any appropriate amount in any suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition.
- the composition may be provided in a dosage form that is suitable for the oral, parenteral (e.g., intravenously, intramuscularly), rectal, cutaneous, nasal, vaginal, inhalant, skin (patch), or ocular administration route.
- the composition may be in the form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, drenches, osmotic delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols.
- the pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A. R. Gennaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
- the invention provides methods for the treatment of AAI (e.g., CM3- and/or 0.19)-related gastrointestinal disorders by administering a subject (e.g., a human) in need thereof an effective amount of a composition that includes an antibody against an AAI protein (e.g., CM3), or a different antibodies against the major AAI variants in cereals.
- AAI e.g., CM3- and/or 0.19
- Such disorders are related to the induction of an innate immune response against AAI proteins (e.g., against CM3 and/or 0.19) after the consumption of an AAI containing food product.
- These disorders include celiac disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastrointestinal hypersensitivity to wheat, as well as other inflammatory disease of the GI tract and related immune and autoimmune disorders.
- the invention provides therapeutic antibodies (e.g., neutralizing antibodies) and diagnostic antibodies against AAI, e.g., against CM3 and/or 0.19.
- therapeutic antibodies e.g., neutralizing antibodies
- diagnostic antibodies against AAI e.g., against CM3 and/or 0.19.
- the antibodies against AAI (e.g., against CM3 and/or 0.19) can be used for diagnostic, research, or therapeutic purposes. Numerous methods for making antibodies are known in the art and can be used in the invention to make such antibodies.
- a coding sequence for an AAI (e.g., a CM3 and/or 0.19) peptide or polypeptide is expressed as a C-terminal fusion with glutathione S-transferase (GST) (Smith et al., Gene 67:31, 1988).
- GST glutathione S-transferase
- the fusion protein is purified on glutathione-Sepharose beads, eluted with glutathione, cleaved with thrombin (at an engineered cleavage site), and purified for immunization of rabbits. Primary immunizations are carried out with Freund's complete adjuvant and subsequent immunizations with Freund's incomplete adjuvant. Antibody titers are monitored by Western blot and immunoprecipitation analyses using the thrombin-cleaved protein fragment of the GST fusion protein. Immune sera are affinity purified using CNBr-Sepharose-coupled protein. Antiserum specificity can be determined using a panel of unrelated GST proteins.
- peptides corresponding to relatively unique immunogenic regions of a polypeptide of the invention can be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine.
- KLH keyhole limpet hemocyanin
- Antiserum to each of these peptides is similarly affinity purified on peptides conjugated to BSA, and specificity is tested by ELISA or Western blot analysis using peptide conjugates, or by Western blot or immunoprecipitation using the polypeptide expressed as a GST fusion protein.
- monoclonal antibodies that specifically bind an AAI can be prepared using standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495, 1975; Kohler et al., Eur. J. Immunol. 6:511, 1976; Kohler et al., Eur. J. Immunol. 6:292, 1976; Hammerling et al., Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981). Once produced, monoclonal antibodies can also be tested for specific recognition by Western blot or immunoprecipitation analysis.
- Antibodies that specifically recognize an AAI protein can be used, for example, in immunoassays or as therapies.
- monoclonal antibodies can be prepared using the polypeptide of the invention described above and a phage display library (Vaughan et al., Nature Biotech. 14:309, 1996).
- Antibodies of the invention can be produced using fragments of the AAI (e.g., a CM3 and/or 0.19) polypeptide that lie outside generally conserved regions and appear likely to be antigenic by criteria such as high frequency of charged residues.
- AAI e.g., a CM3 and/or 0.19 polypeptide that lie outside generally conserved regions and appear likely to be antigenic by criteria such as high frequency of charged residues.
- fragments are generated by standard techniques of PCR and cloned into the pGEX expression vector. Fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix. To minimize potential problems of low affinity or specificity of antisera, two or three such fusions are generated for each protein, and each fusion is injected into at least two rabbits. Antisera are raised by injections in a series, and can include, for example, at least three booster injections.
- the invention also includes various genetically engineered antibodies, humanized antibodies, chimeric antibodies, and antibody fragments, including F(ab′)2, Fab′, Fab, Fv, and sFv fragments.
- Truncated versions of monoclonal antibodies for example, can be produced by recombinant methods in which plasmids are generated that express the desired monoclonal antibody fragment(s) in a suitable host.
- Antibodies can be humanized by methods known in the art, e.g., monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, Calif.). Fully human antibodies, such as those expressed in transgenic animals, are also included in the invention (Green et al., Nature Genetics 7:13-21, 1994).
- Examples of approaches that can be used to generate antibodies of the invention include the following.
- Ladner U.S. Pat. Nos. 4,946,778 and 4,704,692 describes methods for preparing single polypeptide chain antibodies.
- Ward et al. Nature 341:544-546, 1989, describes the preparation of heavy chain variable domains, which they term “single domain antibodies,” and which have high antigen-binding affinities.
- McCafferty et al., Nature 348:552-554, 1990 shows that complete antibody V domains can be displayed on the surface of fd bacteriophage, that the phage bind specifically to antigen, and that rare phage (one in a million) can be isolated after affinity chromatography.
- Boss et al. U.S. Pat. No. 4,816,397, describes various methods for producing immunoglobulins, and immunologically functional fragments thereof, that include at least the variable domains of the heavy and light chains in a single host cell.
- Antibodies to AAI can be used, as noted above, to detect AAI, or to inhibit the biological activities of AAI.
- the antibodies can be coupled to compounds, such as radionuclides and liposomes, for diagnostic uses.
- Polyclonal antibodies can be isolated from the milk or colostrum of, e.g., immunized cows. Bovine colostrum contains 28 g of IgG per liter, while bovine milk contains 1.5 g of IgG per liter (Ontsouka et al. J. Dairy Sci. 86:2005-2011, 2003). Polyclonal antibodies can also be isolated from the yolk of eggs from immunized chickens (Sarker et al. J. Ped. Gastro. Nutr. 32:19-25, 2001).
- Adjuvants useful in this invention include, but are not limited to, Emulsigen®, an oil-in-water emulsified adjuvant, Emulsigen®-D, an oil-in-water emulsified adjuvant with DDA immunostimulant, Emulsigen®-P, an oil-in-water emulsified adjuvant with co-polymer immunostimulant, Emulsigen®-BCL, an oil-in-water emulsified adjuvant with block co-polymer immunostimulant, CarbigenTM, a carbomer base, and PolygenTM, a co-polymer base. All of the listed adjuvants are commercially available from MVP Laboratories in Omaha, Nebr.
- Antibodies useful in this invention can be identified in several different screening assays.
- immunizing antigen e.g., CM3 and/or 0.19.
- ELISA plates are coated with immunogen, the antibody is added to the plate, washed, and the presence of bound antibody detected by using a second antibody specific for the Ig of the species in which the antibody was generated.
- a functional in vitro assay can be used to screen antibodies e.g., an neutralizing assay based on monocyte derived dendritic cells, as described herein.
- the invention provides a therapeutic composition
- a therapeutic composition comprising anti-AAI (e.g., anti-CM3 and/or anti-0.19) antibodies suitable for delivery, preferably oral delivery, to a patient in need thereof, preferably a human patient.
- the pharmaceutical composition may further comprise suitable carriers, adjuvants and other physiologically acceptable excipients.
- the invention also features a therapeutic composition containing antibodies with specificity for both the CM3 of SEQ ID NO:1 (or proteins substantially identical to the protein of SEQ ID NO:1) and/or the 0.19 of SEQ ID NO:2 (or proteins substantially identical to the protein of SEQ ID NO:2) as well as additional CM3- or 0.19-related proteins (e.g., CM3 or 0.19 analogs expressed in other species of cereals or other AAI proteins as disclosed herein).
- Such antibodies can be identified by testing specificity to all of the desired CM3- or 0.19-related proteins.
- compositions containing a plurality of antibodies, where different antibodies in the composition are specific for different analogs of AAI (e.g., CM3 and/or 0.19). Additionally or alternatively, such compositions can contain antibodies against both AAI (e.g., CM3 and/or 0.19), as well as gluten (e.g., gliadin and glutenin fractions, see, e.g., WO 2007/056301, which is herein incorporated by reference in its entirety).
- AAI e.g., CM3 and/or 0.19
- gluten e.g., gliadin and glutenin fractions, see, e.g., WO 2007/056301, which is herein incorporated by reference in its entirety.
- Such pharmaceutical compositions can be achieved by mixing more than one source of antibodies, or, e.g., inoculating an antibody producing animal with more than one AAI (e.g., a cow can be inoculated with variants of CM3 and/or 0.19 with adjuvants as described above thereby creating a mixture of polyclonal antibodies with differing specificities).
- AAI e.g., a cow can be inoculated with variants of CM3 and/or 0.19 with adjuvants as described above thereby creating a mixture of polyclonal antibodies with differing specificities.
- the oral formulations can comprise enteric coatings, so that the active agent is delivered to the intestinal tract.
- Enteric formulations are often used to protect an active ingredient from the strongly acid contents of the stomach.
- Such formulations are created by coating a solid dosage form with a film of a polymer that is insoluble in acid environments and soluble in basic environments.
- Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate, methacrylate copolymers and cellulose acetate phthalate.
- compositions can be administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
- Neutralizing antibodies can be administered to a patient prior to, or concurrently, or after the ingestion of a substance that may contain an AAI (e.g., CM3 and/or 0.19).
- the neutralizing antibodies of the invention can also be administered to the patient on a regular dosing schedule (e.g., one, two, three times a day, or more).
- the neutralizing antibodies can also be administered at a specific time of day, e.g., prior to sleep or upon wakening.
- Detection and measurement of indicators of efficacy may be measured by a number of available diagnostic tools, including but not limited to, for example, by physical examination including blood tests, biopsies of the small intestine, pulmonary function tests, and chest X-rays; CT scan; bronchoscopy; bronchoalveolar lavage; lung biopsy and CT scan.
- Suppression of the innate immunity can be measured, e.g., by quantifying the release of cytokines at the sites of lesions.
- both the physician and patient can identify a reduction in symptoms of a disease.
- compositions of this invention comprise any of the compounds of the present invention, or pharmaceutically acceptable derivatives thereof, together with any pharmaceutically acceptable carrier.
- the dosage and dose rate of the compounds of this invention effective to produce the desired effects will depend on a variety of factors, such as the nature of the antibody, the size of the subject, the goal of the treatment, the nature of the pathology to be treated, the specific pharmaceutical composition used, and the judgment of the treating physician. Dosage levels of between about 0.1 and about 1000 mg/kg body weight per dose, preferably between about 1 and about 500 mg/kg body weight per dose of the active ingredient antibody are useful.
- the antibodies of the invention can also be administered at a dose ranging between about 1 mg/kg body weight/dose and about 200 mg/kg body weight/dose, and between about 5 mg/kg body weight/dose and about 50 mg/kg body weight/dose.
- the invention features assays for detecting AAI (e.g., CM3 and/or 0.19) in food products.
- the assays can contain, e.g., antibodies as described above. Such antibodies can be antibodies specific for AAI proteins (e.g., CM3 and/or 0.19), and can have neutralizing or non-neutralizing activities. Such antibodies can be detectably labeled to facilitate detection.
- Assays for detecting proteins in a sample e.g., a food product
- ELISA or RIA assays e.g., ELISA or RIA assays.
- Such assays can be readily adapted to detection of AAI (e.g., CM3 and/or 0.19).
- the invention also features assays for detecting antibodies against AAI (e.g., CM3 or 0.19) in a patient sample (e.g., using an ELISA assay as described above).
- assays can be used, e.g., to diagnose a patient as being sensitive to AAI (e.g., sensitive to CM3 and/or 0.19, and as having celiac disease, ulcerative colitis, Crohn's disease, or irritable bowel syndrome).
- the patient sample can be any sample likely to contain antibodies against AAI (e.g., a blood sample or stool sample).
- the presence or heightened levels of endogenously generated antibodies against AAI can be indicative of a subject as being sensitive to AAI containing food products.
- the invention also features food products with decreased levels of AAI (e.g., CM3 and/or 0.19).
- Such food products can be prepared, e.g., by degrading or removing AAI prior to consumption.
- Such food products can also be prepared from transgenic cereals (e.g., wheat) containing nucleic acid constructs encoding RNAi molecules against AAI.
- AAI e.g., CM3 and/or 0.19 protein
- disulfide reduction of AAI can be achieved by agents such dithioerithrol, or preferably by a NADP-thioredoxin system as described by Farid et al. (J Agricult Food Chem 56:7146-7150, 2008) for the improvement of digestability of soy flour.
- the latter and related methodologies have the advantage that disulfide reduction is non-toxic.
- the reduced AAIs are then easily degraded by gastric and duodenal proteases, leading to their “detoxification,” i.e., inability to elicit an innate immune response.
- the reduced AAIs can be predigested with common proteases such as pepsin, trypsin, or chymotrypsin, or with specialized enzyme preparations.
- Decreased levels of AAI can also be achieved by separating AAI from the food product by, e.g., exposing the food product to antibodies specific for AAI.
- Such antibodies can be used, e.g., in a purification column to remove AAI from a solution containing AAI.
- RNAi molecules specific for an AAI e.g., against a nucleic acid sequence corresponding to the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2.
- AAI e.g., against a nucleic acid sequence corresponding to the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2.
- Such RNAi molecules can be expressed from a nucleic acid construct introduced into a plant cell.
- expression of the RNAi construct would result in a decrease of CM3 and/or 0.19 expression in the food product of 50%, 60%, 70%, 80%, 90%, 95%, 99%, or greater.
- virus induced gene silencing can be used to decrease CM3 (or other AAIs) expression in, e.g., wheat or other cereals.
- a plant virus e.g., barley stripe mosaic virus
- CM3 or other AAIs
- This technology is reviewed, e.g., in Cakir et al. (Crop Sci. 50:S-1-S-8, 2010), which is hereby incorporated by reference in its entirety.
- gliadin, LPS, and TNF- ⁇ were digested with proteinase K, completely digesting and abrogating all peptide-related activities.
- TNF- ⁇ lost its stimulatory capacity, while LPS was still able to induce IL-8.
- PT gliadin was equally inactivated ( FIG. 1 ), indicating that the stimulatory effects of gliadin were due to protein and not LPS contamination.
- IL-8 expression was comparable, human monocyte-derived dendritic cells (DC) stimulated with PT gliadin expressed TNF- ⁇ and RANTES to a much lesser extent than the LPS stimulated control ( FIG. 8 ).
- DC human monocyte-derived dendritic cells
- a-gliadin peptide p31-43 increases IL-15 secretion in celiac biopsies.
- this peptide did not elicit secretion of IL-8, TNF- ⁇ , or MCP-1 in our monocytic or intestinal epithelial cell lines (HT29, Caco-2 and T84), even at 40 ⁇ g/ml ( FIG. 1 ).
- DC When exposed to PT gliadin and LPS, DC also up-regulated the cell surface maturation markers CD25, CD80, CD83, and CD86 while zein showed no effect ( FIG. 2E ).
- gliadin may signal via MyD88, a key adapter molecule in the toll-like receptor (TLR)/IL-10 pathway. Since MyD88 transmits signals from several TLRs, we studied peritoneal macrophages of C3H/HeJ mice that lack TLR4 responses due to a spontaneous point mutation in the TLR4 gene. In these mice KC (IL-8) and TNF- ⁇ secretion was reduced to baseline levels after gliadin or LPS stimulation compared to syngenic C3H/HeOuJ TLR4 competent mice.
- TLR toll-like receptor
- TLR4 TLR4-CD14-MD2-complex. While non-transfected HEK-293 cells responded neither to gliadin nor to LPS stimulation, both stimulants induced an increase of IL-8 secretion in the transfected cells. Specificity of the transfection was demonstrated by the absence of IL-8 induction by the TLR2 agonist Pam3CSK4 ( FIG. 3 ).
- TLR4 is unique in its ability to mediate cellular activation via two pathways: the adapter molecule MyD88 or via interferon regulatory factor 3 (IRF3) pathway.
- IRF3 interferon regulatory factor 3
- peritoneal macrophages from MyD88 knockout mice displayed markedly reduced KC and TNF- ⁇ secretion after gliadin and LPS stimulation, indicating a major involvement of the MyD88 pathway.
- TLR3 does not use MyD88 as adapter protein for signaling, we used the TLR3 agonist Poly I:C as positive control ( FIG. 4A ).
- gliadin fractions that harbored the stimulatory activity.
- Gliadins from the pure wheat strain “Rektor” were separated into their ⁇ -, ⁇ - and ⁇ -fractions via HPLC.
- the ⁇ -, ⁇ -, ⁇ 1-2-, and ⁇ 5-gliadins, as well as whole gliadin were digested with pepsin and trypsin and first tested on THP-1 monocytic cells.
- IL-8 release was induced strongly by PT-digested ⁇ 1-2- and ⁇ 5-gliadins ( FIG. 4C ).
- a water-soluble gliadin fraction showed the same properties as the PT (omega) gliadins but with an even higher stimulatory capacity than PT gliadin ( FIG. 5E ) and SDS-PAGE demonstrated a more prominent band with a molecular weight of 15 kD which again was confirmed as AAI by mass spectrometry.
- AAI purified from wheat seed to stimulate human monocyte derived dendritic cells. HPLC analysis of this preparation showed one major peak confirming its purity. Both untreated and PT-digested AAI induced increased IL-8 secretion ( FIG. 5 ), while proteinase K digestion abrogated its stimulatory capacity, ruling out LPS contamination ( FIGS. 5D and 5E ). AAI was then incubated with peritoneal macrophages from MyD88 ⁇ / ⁇ and C57BL/6J wildtype mice, showing a lack of KC secretion in MyD88 ⁇ / ⁇ compared to wild type cells.
- mice were gavaged with LPS, water-soluble gliadin, or PBS, followed by measurement of transcript levels of inflammatory cytokines in the proximal duodenum. Only with water-soluble gliadin did we detect a significant upregulation of duodenal KC, MCP-1, and IL-1 ⁇ (but not TNF- ⁇ ) transcripts ( FIG. 6D ). Of note, LPS did not increase any of these cytokines, which is likely due to its inactivation by low pH in the stomach or by intestinal alkaline phosphatase during intestinal passage.
- AAI CM3 and 0.19 were recombinantly expressed in eukaryotic HEK 293 cells, in order to exclude bacterial contaminants, to ensure correct folding, and to identify which of both molecules was the active compound.
- the affinity purified proteins were used to stimulate monocyte derived DCs.
- CM3 and to a lesser degree 0.19 upregulated IL-8 secretion, suggesting that CM3 as well as 0.19 AAI were the active compound ( FIG. 7 ).
- CM3 and 0.19 the main ATI family members, were detected by mass spectrometry and were recombinantly expressed in eukaryotic HEK-293 cells to prevent bacterial contaminants (LPS) and to ensure correct protein folding ( FIGS. 9A and B). Both affinity purified ATIs stimulated TLR4/MD2/CD14-transfected but not untransfected HEK-293 cells confirming their TLR4-stimulating activity. In line with eukaryotic expression, the stimulatory activity of recombinant CM3 and 0.19 was maintained after additional purification using an endotoxin depletion column ( FIG. 9C ).
- Purified cell culture tested LPS E coli 055:B5 and in wheat alpha-amylase inhibitor (AAI) type I were purchased from Sigma-Aldrich (St Louis, Mo.), the TLR2 agonist N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine ⁇ 3 HCl (Pam3CSK4) and the TLR3 agonist Polyinosine-polycytidylic acid (poly-I:C)) were obtained from Invivogen (San Diego, Calif.). Other reagents were of the highest purity available and, if not mentioned otherwise, obtained from Sigma-Aldrich.
- gliadin purchased from Sigma-Aldrich (G3375) was used for experiments. Gliadin from the pure wheat strain ‘Rektor’ was subfractionated as described in the art. Briefly, ⁇ , ⁇ , ⁇ 1.2 and ⁇ 5 gliadins were obtained by HPLC purification on a Nucleosil C8 column (4.6 ⁇ 240 mm) at 50° C., using 0.1% trifluoroacetic acid as phase A, and 99.9% acetonitrile plus 0.1% trifluoroacetic acid as phase B, and a gradient from 24% B to 56% B in 30 min. Detection was at 210 nm. Purity of the fractions was confirmed by SDS PAGE, aminoterminal sequence analysis and their characteristic amino acid composition.
- Pepsin-trypsin-digested (PT-) gliadin was generated as originally described with minor modifications. Briefly, gliadin was digested with pepsin in 0.1M HCL (pH 1.8) at 37° C. for 4 hrs, followed by pH adjustment to 7.8 and digestion with trypsin at 37° C. for 4 hrs (substrate:enzyme ratio of 1:200 for both reactions). Adjustment of the pH to 4.5 resulted in a precipitate which was removed by centrifugation at 2,500 rpm, and N-tosyl-chloromethyl-ketone was added to inhibit residual trypsin activity.
- the supernatant containing the PT-gliadin was dialyzed against 10 mM ammonium carbonate, pH 7.8 (molecular weight exclusion 1000D, Spectra/Por®, Serva, Heidelberg, Germany), sterile-filtered and lyophilized.
- 10 mM ammonium carbonate, pH 7.8 molecular weight exclusion 1000D, Spectra/Por®, Serva, Heidelberg, Germany
- sterile-filtered lyophilized.
- a parallel digest of zein from corn (Sigma-Aldrich) was used as negative control.
- the water soluble fraction of gliadin was obtained by incubating 10 g of gliadin in 50 ml sterile water at 37° C. for 8 hrs under continuous stirring. Insolubles were removed by centrifugation and the supernatant was sterile filtered and lyophilized.
- Peptide p31-43 of ⁇ -gliadin (sequence LGQQQPFPPQQPY (SEQ ID NO:3 and a scrambled control peptide (sequence GLQPFQQPQPPQY (SEQ ID NO:4)) were synthesized by AnaSpec Inc. (San Jose, Calif.). Purity of the peptides was >80% according to HPLC and mass spectrometry analysis. Forty-three 20 mer peptides with an overlap of ten amino acids covering the 440 residue omega 5 gliadin were synthesized at 60-80% purity by Primm Biotechnology (Cambridge, Mass.).
- THP-1, U937, HEK-293 (all from ATCC, Manassas, Va.), and HEK-293 cells stably transfected with the TLR4-CD14-MD2 complex (Invivogen) were cultured in complete RPMI or DMEM (Cellgro, Manassas, Va.) supplemented with penicillin/streptomycin and 10% fetal calf serum at 37° C. in a 5% CO 2 atmosphere.
- peripheral monocytes 40 ml blood was obtained from 11 patients with celiac disease during their diagnostic workup (median 37 years, range 18-59 years), after prior informed consent. Eight patients were on gluten free diet and in clinical remission, three patients were newly diagnosed and therefore on a regular gluten containing diet. Control monocytes were from the buffy coat of leukopheresis concentrates of anonymous blood donors. Whole EDTA blood or leukapheresis concentrates were subjected to density gradient centrifugation over Ficoll-Hypaque (GE Healthcare, Pittsburgh, Pa.) and CD 14-positive monocytes purified by MACS separation according to the manufacturer's protocol (Miltenyi, Bergisch Gladbach, Germany).
- monocytes were cultered in RPMI supplemented with 10% fetal calf serum, 200 U/ml rhIL-4 and 300 U/ml rhGM-CSF (both from PeproTech, Rocky Hill, N.J.) for 6-8 days.
- Murine resident peritoneal macrophages were isolated by peritoneal lavage using a 3 ml syringe and 18 G needles. Three 3 ml of sterile PBS was injected into the peritoneal cavity and reaspirated after gentle massage of the abdomen. For further purification MACS separation for CD11b positive cells was done according to the manufacturer's protocol (Miltenyi).
- PT-gliadin the wheat ATI, LPS, or TNF ⁇ were incubated with or without 20 ⁇ g/ml proteinase K (Promega, Madison, Wis.) for 4 hrs at 56° C. After proteinase K inactivation by boiling for 5 minsute the digests were used for cell stimulation.
- proteinase K Promega, Madison, Wis.
- mice C3H/HeJ, C3H/HeOuJ and Rag1 ⁇ / ⁇ mice were obtained from The Jackson Laboratory (Bar Harbour, Me.).
- the MyD88 ⁇ / ⁇ mice were a kind gift from S. Akira, (Osaka University, Osaka, Japan).
- Congenic C57BL/6J mice served as experimental controls and were bred under the same conditions in the same facility. All experiments were done with mice at age 5-7 weeks.
- mice were injected intraperitoneally with water-soluble gliadin, zein (500 ⁇ g/g body weight) or LPS (1 ⁇ g/g) in 200 ⁇ l PBS, or PBS alone (negative control). 2 hrs after injection, mice were euthanized by ketamine/xylazine administration and blood was drawn by intraorbital bleeding.
- mice were either raised on gluten free diet (C57BL/6J and MyD88 ⁇ / ⁇ mice) or put on gluten free diet for at least two weeks (C3H/HeJ, C3H/HeOuJ mice), and starved the night before the experiment.
- Gluten free feed was obtained from Research Diets (New Brunswick, N.J.). All stimulants were diluted in PBS. Mice were administered gliadin, zein (2 mg/g mouse weight), LPS (20 ⁇ g/g mouse weight), ATI (0.075 mg/g mouse weight) in 200 ⁇ l PBS. Mice were euthanized 4 hrs after gavage and the duodenum snap frozen in liquid nitrogen.
- IL-8, TNF- ⁇ , MCP-1, RANTES, and mouse IL-8 (KC) was determined using validated ELISAs (IL-8, hTNF ⁇ : BD Pharmingen, San Jose, Calif.; MCP-1, hRANTES, mRANTES, KC: R&D Systems, (Minneapolis, Minn.; mTNF ⁇ : eBioscience, San Diego, Calif.), according to the manufacturer's protocols.
- RNA isolation was performed using Trizol reagent (Invitrogen) according to the manufacturer's instructions. Exon-exon boundary spanning primer sequences were obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank/) and sequences are listed in Table [x].
- Real-time PCR was performed using LightCycler 480 SYBR Green I mastermix (Roche, Indianapolis, Ind.) and a Roche LightCycler 480 system. Mouse GAPDH served as endogenous control. PCR was set up in triplicates and threshold cycle (Ct) values of the target genes were normalized to the endogenous control. Differential expression was calculated according to the 2- ⁇ CT method.
- Monocyte derived dendritic cells were seeded at a concentration of 1 ⁇ 10 6 /ml in 96 well plates. Cells were pre-incubated with blocking antibodies (polyclonal rat anti-TLR4, Invivogen, 10 ⁇ g/ml), polyclonal goat anti-CD14, R&D, 20 ⁇ g/ml) for 3 hrs at 37° C. before stimulation.
- blocking antibodies polyclonal rat anti-TLR4, Invivogen, 10 ⁇ g/ml
- polyclonal goat anti-CD14, R&D 20 ⁇ g/ml
- Human monocyte derived DC were stimulated with LPS, PT gliadin, and PT zein overnight.
- FcR blocking reagent Miltenyi
- monoclonal antibodies final concentration 10 ⁇ g/ml, all from eBioscience
- Cells were then washed with staining buffer (PBS, 1% BSA), cell viability was assessed by DAPI exclusion (0.1 ⁇ g/ml, Roche) and only viable cells were analyzed by flow cytometry using a 4 laser LSRII (BD Biosciences) and Flowjo software (Tree Star, Inc.).
- CM3 or 0.19 were generated in a eukaryotic system using the expression vector pCDNA (Invitrogen) and HEK 293 cells.
- cDNA was optimized and synthesized by genscript (sequence number AY436554.1) and correct orientation was checked by sequencing analysis.
- the expressed protein was purified from supernatant with anti-flag agarose beads in batch technique according to the manufacturer's protocol (Sigma).
- CM3 and 0.19 were generated in eukaryotic HEK-293 cells, using cDNAs optimized to fit eukaryotic codon usage (Genscript, Pscataway, N.J.; CM3 and 0.19 with NCBI GenBank sequence numbers AY436554.1 and AY729672.1, respectively). cDNAs were cloned into pUC57 and correct reading frames and orientations confirmed by sequence analysis and KpnI-ApaI restriction. CM3 and 0.19 open reading frames were then cloned into pcDNA3.1 (+) (Invitrogen).
- the HindIII-KpnI fragment of the PCR product was fused with the Flag-tag at the N- instead of the C-terminus using the forward primer 5′-CCCAAGCTTAGCGGACCCTGGATGTGCTAC and the reverse primer 5′-CGGGGTACCCCTCAGGCGTCAGGGTAAGCGGCCAC.
- the CM3 and 0.19 constructs were then subcloned into the pFLAG-CMV4 vector (Sigma-Aldrich) and the correct orientation was confirmed by sequencing with the N-terminal sequencing primer 5′-AATGTCGTAATAACCCCGCCCC-GTTGACGC.
- HEK-293 cells cultured on 10 cm tissue culture dishes were transfected with 10 ⁇ g of plasmid DNA encoding CM3 and 0.19 using lipofectamine 2000 (Invitrogen), followed by incubation in DMEM (Mediatech) containing 1% fetal bovine serum and 100 IU penicillin/100 ⁇ g/ml streptomycin for 48 h. The media were obtained by centrifugation at 4,500 rpm for 10 min at 4° C.
- CM3 protein While sufficient CM3 protein was secreted into the media, 0.19 ATI had to be isolated from the detergent-soluble fraction. Briefly, HEK-cells expressing 0.19 were washed with ice cold-PBS, resuspended in 50 ml of buffer C for 15 min on ice, and centrifuged at 14,000 rpm for 20 min at 4° C. Thus, the solubilized 0.19 and soluble CM3 were bound to Flag-M2 agarose (Sigma-Aldrich) pre-equilibrated with buffer C by gentle shaking for 3 h at 4° C., washed three times with buffer C, and further washed three times with buffer D (Buffer C without detergents).
- Flag-M2 agarose Sigma-Aldrich
- ATIs were eluted with TBS [pH 7.4] containing Flag peptide (Sigma-Aldrich). In order to rigorously exclude endotoxin, eluted CM3 and 0.19 were also applied to an entotoxin removal column (Norgen Biotek corp., Thorold, ON, Canada). ATIs were the used at 5 ⁇ g/ml to stimulate HEK-293 cells stably transfected with the TLR4-CD14-MD2 complex, and IL-8 secretion was quantified after 24 h using the IL-8 ELISA as described above.
- HEK-293 cells stably expressing TLR4-CD14-MD2 were induced to express CM3 or 0.19, respectively, followed by cell lysis in buffer C. Lysates were cleared by centrifugation at 14,000 rpm for 20 min at 4° C., and 50 ⁇ g of protein run on a 15% SDS-gel and subjected to Western blotting to analyze activation of the canonical and the alternative (p-IRF3) pathways using antibodies to phosphorylated and unphosphorylated (p-NF- ⁇ B/p65) and IRF3 (all from Cell Signaling Technology, Danvers, Mass.).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Botany (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- This application claims benefit of U.S. Provisional Application Nos. 61/330,043, filed Apr. 30, 2010 and 61/417,613 filed Nov. 29, 2010, each of which is hereby incorporated by reference.
- This work was supported by grant number NIH 1R21AI078385A1-01 from the United States National Institutes of Health. The Government has certain rights in the invention.
- This invention relates to the treatment of celiac disease with compounds that decrease inflammation resulting from contact with wheat alpha Amylase inhibitors, including CM3 or 0.19.
- Celiac disease (CD) is an inflammatory small intestinal disorder, often accompanied by a malabsorptive syndrome which is caused in part by an uncontrolled immune reaction to ingested gluten proteins. The prevalence of this disease in affected populations such as the US, the Middle East, or Europe is 0.5-2.5%. Untreated, CD patients can develop serious secondary morbidity, such as T cell lymphoma and autoimmune diseases. The disorder is considered to be the result of a complex interplay of intrinsic (genetic) and variable extrinsic (environmental) factors that explain the wide spectrum of clinical manifestations ranging from asymptomatic to severe malabsorption. Gluten peptides are efficiently presented by celiac disease-specific HLA-DQ2- and HLA-DQ8-positive antigen-presenting cells, and thus drive the adaptive immune response, predominantly in the connective tissue of the lamina propria. Tissue transglutaminase (tTG), which has been identified as the highly specific endomysial autoantigen, is increasingly released from cells during inflammation. It usually potentiates antigen presentation by HLA-DQ2 and HLA-DQ8 by deamidating and cross-linking gluten peptides. The result is lamina propria T-cell activation and mucosal transformation by activated intestinal mononuclear cells and fibroblasts.
- Currently, celiac disease is typically treated with a strict gluten free diet. However, a gluten free diet is difficult to maintain and non-dietary treatment alternatives are urgently needed. Moreover, even a gluten free diet may not lead to remission in patients with refractory celiac disease.
- The invention features a pharmaceutical composition including an antibody (e.g., a polyclonal, monoclonal, or humanized antibody) against alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, alpha amylase inhibitor 0.53 (0.53), and structurally and functionally related molecules (collectively termed AAI). The antibody can be formulated for, e.g., oral administration (e.g., in milk or colostrum). Furthermore, the antibody can be produced in the milk or colostrum of a mammal (e.g., goat or cow). Also, the antibody can be formulated to be active in the intestine.
- In another aspect, the invention features a method of treating a gastrointestinal disorder (e.g., celiac disease, ulcerative colitis, Crohn's disease, or irritable bowel syndrome) by administering any of the pharmaceutical compositions described above or an oral or systemic TLR4 inhibitor (e.g., as described below). The pharmaceutical composition can be administered immediately prior to, during or after a meal, or can be administered, e.g., once, twice, or three times daily.
- In another aspect, the invention features a method of determining a substance's potency in inducing a negative gastrointestinal reaction by measuring the AAI content of the substance, where the measurement is indicative of the potency of the substance in inducing a negative gastrointestinal reaction. This method can include dispersing all or a fraction of the substance in an aqueous solution, contacting the solution with an antibody specific for an AAI (e.g., an antibody bound to a substrate) under conditions conducive to specific binding, and measuring the amount of the antibody bound to the AAI. In one embodiment, this method features an ELISA assay.
- In another aspect, the invention features a method of testing the sensitivity of a subject to ingestion of AAI containing substances by measuring the levels (e.g., with an ELISA assay) of anti-AAI antibody in sample isolated from the subject (e.g., a blood or stool sample) where the levels are indicative of the sensitivity of the subject to ingestion of AAI containing substances.
- In yet another aspect, the invention features a method of reducing the potency of a substance in inducing a negative gastrointestinal reaction by reducing the AAI content of the substance (e.g., through enzymatic degradation, disulfide reduction, or separation of AAI).
- In a related aspect, the invention features a cereal product (e.g., wheat, rye, barley, oats, corn or rice) including reduced levels of AAI protein (e.g., through enzymatic degradation, disulfide reduction, separation, or by derivation from cereals engineered to express AAI at decreased levels) compared to levels of AAI in naturally occurring cereal products.
- In another aspect, the invention features a nucleic acid construct encoding an RNAi molecule against AAI and a vector including a nucleic acid construct encoding an RNAi molecule against AAI. The invention also features a transgenic plant including any of the above nucleic acid constructs or vectors. These transgenic plants can be processed into food products with decreased AAI content thereby resulting in less potent induction of a negative gastrointestinal reaction in a subject with a gastrointestinal disorder (e.g., celiac disease, ulcerative colitis, and Crohn's disease).
- By “wheat alpha Amylase inhibitor AAI”, and specifically “CM3” and “0.19,” is meant any polypeptide having the activity of full-length CM3 or 0.19 protein:
-
CM3: (SEQ ID NO: 1) MACKSSCSLLLLAAVLLSVLAAASASGSCVPGVAFRTNLLPHCRDYVL QQTCGTFTPGSLPEWMTSASIYSPGKPYLAKLYCCQELAEISQQCRCEA LRYFIALPVPSQPVDPRSGNVGESGLIDLPGCPREMQWDFVRLLVAPGQ CNLATIHNVRYCPAVEQPLWIDYKDDDDK. 0.19: (SEQ ID NO: 2) SGPWMCYPGQAFQVPALPACRPLLRLQCNGSQVPEAVLRDCCQQLAHIS EWCRCGALYSMLDSMYKEHGAQEGQAGTGAFPRCRREVVKLTAASITAV CRLPIVVDASGDGAYVCKDVAAYPD - The terms “wheat alpha Amylase inhibitor CM3”, or “CM3”, “wheat alpha Amylase inhibitor 0.19,” or “0.19” also are used herein to refer to CM3 or 0.19 fragments, which may be, e.g., functional, antigenic, and/or immunogenic. Further, these terms also encompass CM3 or 0.19 polypeptides or fragments including additional terminal amino acids, e.g., an amino terminal methionine.
- By “the activity of full-length CM3 protein”, or “the activity of full-length 0.19 protein” is meant binding to TLR4 and induction of IL-8 secretion in monocytes, macrophages, or dendridic cells as described herein.
- The terms “wheat alpha Amylase inhibitor CM3,” “CM3,” “wheat alpha Amylase inhibitor 0.19,” or “0.19” are also used herein to refer to proteins or peptides having at least 20%, e.g., at least 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) amino acid sequence identity to the sequence of SEQ ID NO:1 or SEQ ID NO:2. Proteins having such amino acid sequence identity can, e.g., have cysteine residues at positions corresponding to the amino acid residue located in the CM3 protein at
residue numbers - The terms “CM1,” “CM2,” “CMa,” “CMd,” “CM16,” “CMb,” “CMX1/CMX3,” “CMX2,” and “alpha amylase inhibitor 0.53” (0.53) are used herein to refer to protein fragments, which may be, e.g., functional, antigenic, and/or immunogenic. Further, these terms also encompass CM1, CM2, CMa, 5 CMd, CM16, CMb, CMX1/CMX3, CMX2, and 0.53 polypeptides or fragments including additional terminal amino acids, e.g., an amino terminal methionine.
- The terms “CM1,” “CM2,” “CMa,” “CMd,” “CM16,” “CMb,” “CMX1/CMX3,” “CMX2,” and 0.53 are also used herein to refer to proteins or peptides having at least 20%, e.g., at least 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) amino acid sequence identity to the sequence of SEQ ID NOs: 6-11, respectively having the activity of binding to TLR4 and induction of IL-8 secretion in monocytes, macrophages, or dendridic cells as described herein. Proteins having such amino acid sequence identity can, e.g., have cysteine residues at positions corresponding to the amino acid residue located in the CM3 protein at
residue numbers - By “polypeptide,” “polypeptide fragment,” or “peptide” is meant a chain of two or more (e.g., 10, 15, 20, 30, 50, 100, or 175, or more) amino acids, regardless of any post-translational modification (e.g., glycosylation or phosphorylation), constituting all or part of a naturally or non-naturally occurring polypeptide, fragment, or peptide. By “post-translational modification” is meant any change to a polypeptide or polypeptide fragment made during or after synthesis. Post-translational modifications can be produced naturally (such as during synthesis within a cell) or generated artificially (such as by recombinant or chemical means). A “protein” can be made up of one or more polypeptides.
- The term “identity” is used herein to describe the relationship of the sequence of a particular nucleic acid molecule or polypeptide (or a fragment thereof) to the sequence of a reference molecule of the same type (or a fragment thereof). For example, if a nucleic acid or amino acid molecule has the same nucleotide or amino acid residue at a given position, as compared to a reference molecule to which it is aligned, there is said to be “identity” at that position. The level of sequence identity of a nucleic acid molecule or a polypeptide to a reference molecule is typically measured using sequence analysis software with the default parameters specified therein, such as the introduction of gaps to achieve an optimal alignment (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, or PILEUP/PRETTYBOX programs). These software programs match identical or similar sequences by assigning degrees of identity to various substitutions, deletions, or other modifications.
- The sequence of a nucleic acid molecule or polypeptide is said to be “substantially identical” to that of a reference molecule if it exhibits, over its entire length, at least 51%, e.g., at least 55%, 60%, 65%, 75%, 85%, 90%, or 95% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the sequence of the reference molecule. For polypeptides, the length of comparison sequences may be, for example, at least 10, 15, 20, 30, 50, 100, or 175, or more amino acids.
- A molecule, e.g., an oligonucleotide probe or primer, a gene or fragment thereof, a cDNA molecule, a polypeptide, or an antibody, can be said to be “detectably-labeled” if it is marked in such a way that its presence can be directly identified in a sample. Methods for detectably labeling molecules are well known in the art and include, without limitation, radioactive labeling (e.g., with an isotope, such as 32P or 35S) and nonradioactive labeling (e.g., with a fluorescent label, such as fluorescein).
- By a “substantially pure” polypeptide (e.g., antibody) is meant a polypeptide (or a fragment thereof) that has been separated from proteins and organic molecules that naturally accompany it. Typically, a polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally occurring organic molecules with which it is naturally associated. For example, the polypeptide can be a polypeptide that is at least 75%, 90%, or 99%, by weight, pure. A substantially pure polypeptide can be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid molecule encoding a polypeptide, or by chemical synthesis. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- A polypeptide is substantially free of naturally associated components when it is separated from those proteins and organic molecules that accompany it in its natural state. Thus, a protein that is chemically synthesized or produced in a cellular system that is different from the cell in which it is naturally produced is substantially free from its naturally associated components. Accordingly, substantially pure polypeptides not only include those that are derived from eukaryotic organisms, but also those synthesized in E. coli, other prokaryotes, or in other such systems.
- An antibody is said to “specifically bind” to a polypeptide or fragment if it recognizes and binds to the polypeptide (e.g., CM3 or 0.19), but does not substantially recognize and bind to other molecules (e.g., non-CM3- or non-0.19-related polypeptides) in a sample, e.g., a biological sample that includes the polypeptide.
- By “neutralization” and “neutralizing” is meant partial or complete attenuation of the biological effects of an AAI (e.g., CM3 and/or 0.19) (e.g., a negative gastrointestinal reaction). Such partial or complete attenuation of the biological effects of AAI results from modification, interruption, and/or abrogation of AAI stimulation of the innate immune response (e.g., as exhibited in celiac disease). As one of skill in the art understands, there exist multiple modes of determining whether an agent, for example an antibody is to be classified as neutralizing. Neutralizing antibodies would, for example, block stimulation of monocytes or dendridic cells by AAI (e.g., CM3 and/or 0.19) in the assays described herein (e.g., by decreasing secretion of IL-8 by 70%, 80%, 90%, 95%, 99%, or greater compared to control). Neutralizing antibodies can also block AAI (e.g., CM3 and/or 0.19) binding to TLR4 (e.g., by decreasing binding by 70%, 80%, 90%, 95%, 99%, or greater compared to control).
- By “sample” is meant a tissue biopsy, amniotic fluid, cell, blood, serum, urine, stool, or other specimen obtained from a patient or a test subject. For example, ELISA and other immunoassays can be used to measure levels of AAI (e.g., CM3 and 0.19); and PCR or RT/PCR can be used to measure the level of AAI (e.g., CM3 and 0.19) nucleic acid molecules.
- By “negative gastrointestinal reaction” is meant an innate immune response triggered by AAI (e.g., CM3 and/or 0.19) that results in undesirable symptoms (e.g., those associated with celiac disease).
- By “potency” is meant the degree to which a substance induces an innate immune response against AAI protein (e.g., CM3 and/or 0.19 protein).
- By “treating” is meant administering a pharmaceutical composition for prophylactic and/or therapeutic purposes or administering treatment to a subject already suffering from a disease to improve the subject's condition or to a subject who is at risk of developing a disease. As it pertains to gastrointestinal disorders, treating can include improving or ameliorating the symptoms of an undesired immune response triggered by AAI (e.g., CM3 and/or 0.19), and prophylactic treatment can include preventing the progression of a mild gastrointestinal disorder to a more serious form. Treating may also mean to prevent the onset of an negative gastrointestinal reaction.
-
FIGS. 1A-1D are a series of graphs showing IL-8, TNF-α, and MCP-1 release in cells treated with the indicated compounds. The experiments ofFIGS. 1A and 1C were conducted in monocytic THP-1 cells and the experiments ofFIGS. 1B and 1D were conducted in monocytic U937 cells. -
FIG. 1E is a graph showing expression of IL-8 in HT29 (intestinal epithelial), U937, and THP-1 cells treated with alpha-gliadin peptide p31-43 and a scrambled control peptide. -
FIG. 1F is a graph showing expression of IL-8 in THP-1 cells treated with the indicated compounds and treated and untreated with proteinase K. -
FIG. 2A is a graph showing IL-8 expression in monocyte derived dendritic cells of healthy control patients or of celiac disease patients on the indicated diet treated with the indicated compound. -
FIG. 2B is a graph showing IL-8 expression of monocyte derived dendritic cells from a healthy control in response to various doses of pepsin/trypsin digested (PT) gliadin. Stimulation with LPS and PT zein served as positive and negative controls, respectively. -
FIG. 2C is a series of graphs showing a flow cytometric analysis of dendritic cells of healthy controls stimulated with PT gliadin. Upregulation of dendritic cell surface maturation markers can be observed in the grey filled and the dotted histogram that represent PT gliadin and LPS stimulation, respectively, whereas PT zein stimulation (non filled) overlaps with the non stimulated control. -
FIGS. 3A and 3B are graphs showing KC (rodent IL-8) and TNF-α expression in peritoneal macrophages isolated from TLR4 deficient C3H/HeJ mice compared to C3H/HOuJ wildtype mice stimulated with LPS or PT gliadin. The TLR2 agonist Pam3CSK4 served as positive control. -
FIGS. 3C and 3D are graphs showing expression of IL-8 secretion upon PT gliadin and LPS stimulation in 293 cells transfected with the TLR4-MD2-CD14 complex (3D) and in non transfected cells (3C). LPS and PMA served as positive, the TLR2 agonist Pam3CSK4 as negative controls. -
FIG. 3E is a graph showing IL-8 secretion in monocyte derived dendridic cells stimulated with PT gliadin and LPS with peritoneal macrophages preincubated with anti-TLR4 and anti-CD14 antibodies. TLR2 agonist Pam3CSK4 and TLR3 agonist Poly I:C served as positive controls. -
FIG. 4A is a graph showing TNF-alpha secretion in peritoneal macrophages isolated from MyD88−/− mice compared to C57BL/6 wildtype mice upon PT gliadin stimulation. LPS served as positive control for the MyD88 knockdown, TLR3 agonist Poly I:C served as cell viability control. -
FIG. 4B is a graph showing RANTES secretion in peritoneal macrophages isolated from C57BL/6J mice upon LPS, Poly I:C and PT gliadin stimulation. -
FIG. 4C is a graph showing stimulation of THP-1 cells with α-, γ-, ω1.2 and ω5-gliadin fractions isolated from the pure wheat strain ‘Rektor’. Co-incubation of α- and γ-gliadin with regular PT gliadin from Sigma served as cell viability control. -
FIGS. 4D and 4E are graphs showing IL-8 secretion in TLR4 transfected (4D) and untransfected (4E) HEK-293 cells treated with ω-gliadins. -
FIG. 4F is a graph showing IL-8 secretion in TLR4 transfected HEK-293 cells treated with synthetic overlapping 20 mers of co5-gliadin. For illustration purposes, nine fractions each were pooled in the stimulation experiments, as well as all 43 fractions. LPS served as positive and Pam3CSK4 or PT zein as negative controls. -
FIGS. 5A and 5B are graphs showing KC expression by monocyte derived dendritic cells stimulated with water-soluble (ws) gliadin (5A) or alpha amylase trypsin inhibitor (ATI, 5B). -
FIG. 5C is a graph showing IL-8 secretion in dendritic cells treated with a proteinase K digestion of ATI and LPS. -
FIG. 5D is a graph showing KC secretion in peritoneal macrophages isolated from MyD88−/− mice compared to C57BL/6J wildtype mice upon ATI or ws gliadin stimulation. -
FIGS. 5E and 5F are graphs showing IL-8 secretion upon PT gliadin, ATI, or LPS stimulation in 293 cells transfected with the TLR4-MD2-CD14 complex (5E) and in non transfected cells (5F). LPS and water-soluble zein served as positive and negative controls, respectively. -
FIG. 6A is a graph showing IL-8 secretion in monocyte derived dendritic cells stimulated with ATI and LPS and preincubated with anti-TLR4 or anti-CD14 antibodies. TLR2 agonist Pam3CSK4 served as positive control. -
FIGS. 6B and 6C are graphs showing serum cytokine levels in C57BL/6J, MyD88−/− (6B), and Rag1−/− mice (6C) (n=4 animals per group) having undergone intraperitoneal injection of LPS (1 μg mouse), ws gliadin (500 μg/g mouse), or ws zein (500 μg/g mouse). Serum was taken 2 hrs after injection and serum cytokine levels were measured by ELISA. -
FIGS. 6D , 6E, and 6F are graphs showing cytokine mRNA expression levels in mice gavaged with LPS (20 μg/g mouse weight), ws gliadin (2 mg/g mouse weight), ATI (0.075 mg/g mouse weight), ws zein (2 mg/g mouse weight), or PBS. 4 hrs after gavage the C57BL/6J, C3H/HeJ, and C3H/HouJ mice were euthanized and duodenal samples were snap frozen in liquid nitrogen. Duodenal cytokine mRNA levels were measured by quantitative RT PCR. (n=3 animals per group). -
FIG. 7A is a western blot showing the major ATI variant CM3 was expressed in eukaryotic 293 cells and purified as Flag-tagged molecule, yielding the expected molecular weights of 16 kD. -
FIG. 7B is a graph showing IL-8 secretion in human dendritic cells upon stimulation with ATI and the recombinant CM3 variant. -
FIG. 7C is a western blot showing expression of NF-κB and the alternative (IRF3) pathways in CM3 and TLR4-transfected HEK cells. -
FIG. 7D is a photomicrograph showing apoptosis in TLR4- and CM3-transfected and untransfected HEK cells. -
FIGS. 8A-8C are supplementary graphs showing expression of IL-8 (8A), TNF-α (8B), and RANTES (8C) in gliadin stimulated human monocyte derived DC from healthy controls. -
FIG. 9A is a western blot showing CM3 and 0.19 expression in HEK-293 cells and purification as Flag-tagged molecules. Western analysis yielded the expected molecular weights of 15 and 17 kDa, respectively, after 15% SDS-PAGE and Western blotting with Flag antibody. No expression in mock (vector only) transfected cells. 0.19 was not secreted into media, but could be recovered in SDS/DTT buffer (Cell), deoxycholate and Triton X-100 buffer (Sup), or the remaining cell pellet. -
FIG. 9B is a Coomassie blue stain (left panel) or western blot using Flag antibody (right panel) showing purity of CM3 and 0.19 ATI after affinity purification on Flag-agarose (15% SDS-PAGE). -
FIG. 9C is a graph showing IL-8 secretion by TLR4-CD14-MD2 expressing HEK-293 cells treated with recombinant ATI. Cells were left untreated, or stimulated with affinity purified detergent extracts from mock-transfected cells, from recombinant CM3, 0.19, or with ATI isolated from wheat (all 5 μg/ml). Controls were Flag peptide (5 μg/ml), PT-gliadin (100 μg/ml), and LPS (10 ng/ml). Representative experiment performed in triplicate. -
FIG. 9D is a western blot showing expression of CM3 and 0.19 in TLR4-CD14-MD2 expressing HEK-293 cells (HEK-TLR4) induces downstream signaling of the canonical (p-NF-κB/p65) and the alternative (p-IRF3) pathways. Western blots of whole cell lysates (50 μg protein). -
FIGS. 10A and 10B are a sequence alignments.FIG. 10A shows an alignment between CM3 and 0.19.FIG. 10B shows an alignment between CM3 or 0.19 and other ATIs from wheat and barley (CMa, CMb, CMd) (SEQ ID NOs, in order listed are SEQ ID NOs:: 3-5, 1, 6-10, 2, and 11). The sequence alignment was prepared using the ClustalW program (2.0.12 version). The highly conserved cysteine residues are boxed. (*), (:), and (.) denote identity, high homology, and low homology, of amino acid residues, respectively. Similarities are much higher among individual ATIs. - In general, the invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, alpha Amylase Inhibitor 0.53 (0.53) (collectively termed AAI), and other structurally and functionally related molecules. To this end, the invention provides pharmaceutical compositions including neutralizing antibodies to alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, alpha Amylase Inhibitor 0.53 (0.53), and other structurally and functionally related molecules, food products containing reduced levels of AAI proteins, assays for identifying AAI protein content in food products, and assays for diagnosing subjects with a disorder related to AAI-triggered innate immune responses. The invention also features methods of treating gastrointestinal disorders associated with an innate immune response to these molecules with preferably, but not exclusively orally active TLR4 inhibitors.
- We discovered that CM3 and/or 0.19 (among other AAIs) contributes to the activation of innate immunity in patients with celiac disease. An exemplary wheat CM3 protein has the sequence of
-
(SEQ ID NO: 1) MACKSSCSLLLLAAVLLSVLAAASASGSCVPGVAFRTNLLPHCRDYVL QQTCGTFTPGSLPEWMTSASIYSPGKPYLAKLYCCQELAEISQQCRCEA LRYFIALPVPSQPVDPRSGNVGESGLIDLPGCPREMQWDFVRLLVAPGQ CNLATIHNVRYCPAVEQPLWIDYKDDDDK.
An exemplary wheat 0.19 protein has the sequence of: -
(SEQ ID NO: 2) SGPWMCYPGQAFQVPALPACRPLLRLQCNGSQVPEAVLRDCCQQLAHIS EWCRCGALYSMLDSMYKEHGAQEGQAGTGAFPRCRREVVKLTAASITAV CRLPIVVDASGDGAYVCKDVAAYPD - The invention provides methods for the treatment of negative gastrointestinal reactions to other cereal-based (e.g., barley, rye, oats, corn, and rice) CM3 or 0.19 proteins, or related molecules, e.g., those set forth in Tables 1 and 2.
-
TABLE 1 Accession Description P17314.1 Alpha-amylase/trypsin inhibitor CM3; P11643.2 Alpha-amylase/trypsin inhibitor CMd; [Hordeum vulgare] CAA49536.1 CMd subunit of tetrameric alpha-amylase inhibitor [Hordeum vulgare] AAB63440.1 CMd3 protein [Hordeum vulgare] CAA31585.1 CMd preprotein (AA −14 to 146) [Hordeum vulgare subsp. vulgare] 1208404B trypsin/amylase inhibitor pUP38 P16159.1 Alpha-amylase/trypsin inhibitor CM16; [Triticum aestivum] P32936.2 Alpha-amylase/trypsin inhibitor CMb; [Hordeum vulgare subsp. vulgare] -
TABLE 2 Accession Description HSSA Alpha-amylase/trypsin inhibitor 0.19 [Triticum aestivum] HSSB Alpha-amylase/trypsin inhibitor 0.19 [Triticum aestivum] HSSC Alpha-amylase/trypsin inhibitor 0.19 [Triticum aestivum] HSSD Alpha-amylase/trypsin inhibitor 0.19 [Triticum aestivum] PO1085.1 Alpha-amylase/trypsin inhibitor 0.19 [Aegilops tauschii] BAA20139.1 Alpha-amylase/trypsin inhibitor 0.19 [Aegilops tauschii] - A sequence comparison with a wide spectrum of other ATIs from wheat and barley (those sequences that are published in common sequence databases) show again largely conserved cysteine residues and neighbouring amino acid residues (
FIG. 10B ), indicating that these will also bind to and activate TLR4. Additional variants of CM3 and 0.19 and related molecules are known in the art and can be identified through standard means. - TLR4 inhibitors for pharmaceutical use are known in the art. Such inhibitors include synthetic gluco-disaccharides such as RSCL-0409 (Kalluri et al. FEBS J. 2010 April; 277(7):1639-52); TLR4 (MD2-TLR4) blocking antibodies (Ungaro et al. Am J Physiol Gastrointest Liver Physiol. 2009 June; 296(6):G1167-79); phosphatidyl-ethanolamine (Lee et al. Mol Cells. 2009 Feb. 28; 27(2):251-5); peptide antagonists (Slivka et al. Chembiochem. 2009 Mar. 2; 10(4):645-9); eritoram tetrasodium, E5564 (Rossignol et al. Innate Immun. 2008 December; 14(6):383-94; Kim et al. Cell. 2007 Sep. 7; 130(5):906-17; and Shimamoto et al. Circulation. 2006 Jul. 4; 114(1 Suppl):I270-4); tetra- or penta-acetylated lipid A (Zhang et al. Org Biomol Chem. 2008 Sep. 21; 6(18):3371-81; Coats et al. J Immunol. 2005 Oct. 1; 175(7):4490-8); blocking LPS variants such as LPS from cyanobacteria, Rhodobacter capsulates, Porphyromonas gingivalis and Capnocytophagatochracea or Helicobacter pylori (Ianaro et al. Mini Rev Med Chem. 2009 Mar; 9(3):306-17; Jemmett et al. Infect Immun. 2008 July; 76(7):3156-63; and Macagno A, et al. J Exp Med. 2006 Jun. 12; 203(6):1481-92), Bartonella Quintana (Popa et al. Infect Immun 2007 October; 75(10):4831-7), Treponema (Lee et al. Microbiology. 2006 February; 152(Pt 2):535-46), or lipid IVa (Saitoh et al. Int Immunol. 2004 July; 16(7):961-9); E5531 (Bryant et al. Vet Immunol Immunopathol. 2007 Apr. 15; 116(3-4):182-9); soluble MD-2/TLR4 complex (Mitsuzawa et al. J Immunol. 2006 Dec. 1; 177(11):8133-9); including indirect negative modulators of TLR4 (MD2-TLR4), such as vitamin D (Sadeghi et al. Eur J Immunol. 2006 February; 36(2):361-70), testosterone derivatives (Norataet al. J Clin Endocrinol Metab. 2006 February; 91(2):546-54), CRX526 (Ianaro et al.), or inhibitors of the nicotinic acetylcholine receptor (Hamano et al. Shock. 2006 October; 26(4):358-64). Each of the above references is incorporated by reference in its entirety.
- Any of the agents employed according to the present invention may be contained in any appropriate amount in any suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition. The composition may be provided in a dosage form that is suitable for the oral, parenteral (e.g., intravenously, intramuscularly), rectal, cutaneous, nasal, vaginal, inhalant, skin (patch), or ocular administration route. Thus, the composition may be in the form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, drenches, osmotic delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols. The pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, 20th edition, 2000, ed. A. R. Gennaro, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
- The invention provides methods for the treatment of AAI (e.g., CM3- and/or 0.19)-related gastrointestinal disorders by administering a subject (e.g., a human) in need thereof an effective amount of a composition that includes an antibody against an AAI protein (e.g., CM3), or a different antibodies against the major AAI variants in cereals. Such disorders are related to the induction of an innate immune response against AAI proteins (e.g., against CM3 and/or 0.19) after the consumption of an AAI containing food product. These disorders include celiac disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastrointestinal hypersensitivity to wheat, as well as other inflammatory disease of the GI tract and related immune and autoimmune disorders.
- The invention provides therapeutic antibodies (e.g., neutralizing antibodies) and diagnostic antibodies against AAI, e.g., against CM3 and/or 0.19.
- The antibodies (e.g., monoclonal, polyclonal, poly-specific, or mono-specific antibodies) against AAI (e.g., against CM3 and/or 0.19) can be used for diagnostic, research, or therapeutic purposes. Numerous methods for making antibodies are known in the art and can be used in the invention to make such antibodies. In one example, a coding sequence for an AAI (e.g., a CM3 and/or 0.19) peptide or polypeptide is expressed as a C-terminal fusion with glutathione S-transferase (GST) (Smith et al., Gene 67:31, 1988). The fusion protein is purified on glutathione-Sepharose beads, eluted with glutathione, cleaved with thrombin (at an engineered cleavage site), and purified for immunization of rabbits. Primary immunizations are carried out with Freund's complete adjuvant and subsequent immunizations with Freund's incomplete adjuvant. Antibody titers are monitored by Western blot and immunoprecipitation analyses using the thrombin-cleaved protein fragment of the GST fusion protein. Immune sera are affinity purified using CNBr-Sepharose-coupled protein. Antiserum specificity can be determined using a panel of unrelated GST proteins.
- As an alternate or adjunct immunogen to GST fusion proteins, peptides corresponding to relatively unique immunogenic regions of a polypeptide of the invention can be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine. Antiserum to each of these peptides is similarly affinity purified on peptides conjugated to BSA, and specificity is tested by ELISA or Western blot analysis using peptide conjugates, or by Western blot or immunoprecipitation using the polypeptide expressed as a GST fusion protein. Alternatively, monoclonal antibodies that specifically bind an AAI (e.g., CM3 or 0.19) can be prepared using standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495, 1975; Kohler et al., Eur. J. Immunol. 6:511, 1976; Kohler et al., Eur. J. Immunol. 6:292, 1976; Hammerling et al., Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981). Once produced, monoclonal antibodies can also be tested for specific recognition by Western blot or immunoprecipitation analysis. Antibodies that specifically recognize an AAI protein (e.g., CM3 or 0.19) can be used, for example, in immunoassays or as therapies. Alternatively monoclonal antibodies can be prepared using the polypeptide of the invention described above and a phage display library (Vaughan et al., Nature Biotech. 14:309, 1996).
- Antibodies of the invention can be produced using fragments of the AAI (e.g., a CM3 and/or 0.19) polypeptide that lie outside generally conserved regions and appear likely to be antigenic by criteria such as high frequency of charged residues. In one specific example, such fragments are generated by standard techniques of PCR and cloned into the pGEX expression vector. Fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix. To minimize potential problems of low affinity or specificity of antisera, two or three such fusions are generated for each protein, and each fusion is injected into at least two rabbits. Antisera are raised by injections in a series, and can include, for example, at least three booster injections.
- In addition to intact monoclonal and polyclonal anti-AAI (e.g., anti-CM3 and/or 0.19) antibodies, the invention also includes various genetically engineered antibodies, humanized antibodies, chimeric antibodies, and antibody fragments, including F(ab′)2, Fab′, Fab, Fv, and sFv fragments. Truncated versions of monoclonal antibodies, for example, can be produced by recombinant methods in which plasmids are generated that express the desired monoclonal antibody fragment(s) in a suitable host. Antibodies can be humanized by methods known in the art, e.g., monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, Calif.). Fully human antibodies, such as those expressed in transgenic animals, are also included in the invention (Green et al., Nature Genetics 7:13-21, 1994).
- Examples of approaches that can be used to generate antibodies of the invention include the following. Ladner (U.S. Pat. Nos. 4,946,778 and 4,704,692) describes methods for preparing single polypeptide chain antibodies. Ward et al., Nature 341:544-546, 1989, describes the preparation of heavy chain variable domains, which they term “single domain antibodies,” and which have high antigen-binding affinities. McCafferty et al., Nature 348:552-554, 1990, shows that complete antibody V domains can be displayed on the surface of fd bacteriophage, that the phage bind specifically to antigen, and that rare phage (one in a million) can be isolated after affinity chromatography. Boss et al., U.S. Pat. No. 4,816,397, describes various methods for producing immunoglobulins, and immunologically functional fragments thereof, that include at least the variable domains of the heavy and light chains in a single host cell. Cabilly et al., U.S. Pat. No. 4,816,567, describes methods for preparing chimeric antibodies.
- Antibodies to AAI (e.g., to CM3 or 0.19) can be used, as noted above, to detect AAI, or to inhibit the biological activities of AAI. In addition, the antibodies can be coupled to compounds, such as radionuclides and liposomes, for diagnostic uses.
- In order to generate polyclonal antibodies on a large scale and at a low cost an appropriate animal species can be chosen. Polyclonal antibodies can be isolated from the milk or colostrum of, e.g., immunized cows. Bovine colostrum contains 28 g of IgG per liter, while bovine milk contains 1.5 g of IgG per liter (Ontsouka et al. J. Dairy Sci. 86:2005-2011, 2003). Polyclonal antibodies can also be isolated from the yolk of eggs from immunized chickens (Sarker et al. J. Ped. Gastro. Nutr. 32:19-25, 2001).
- Multiple adjuvants are approved for use in dairy cows. Adjuvants useful in this invention include, but are not limited to, Emulsigen®, an oil-in-water emulsified adjuvant, Emulsigen®-D, an oil-in-water emulsified adjuvant with DDA immunostimulant, Emulsigen®-P, an oil-in-water emulsified adjuvant with co-polymer immunostimulant, Emulsigen®-BCL, an oil-in-water emulsified adjuvant with block co-polymer immunostimulant, Carbigen™, a carbomer base, and Polygen™, a co-polymer base. All of the listed adjuvants are commercially available from MVP Laboratories in Omaha, Nebr.
- Antibodies useful in this invention can be identified in several different screening assays. First, antibodies are assayed by ELISA to determine whether they are specific for the immunizing antigen (e.g., CM3 and/or 0.19). Using standard techniques, ELISA plates are coated with immunogen, the antibody is added to the plate, washed, and the presence of bound antibody detected by using a second antibody specific for the Ig of the species in which the antibody was generated.
- A functional in vitro assay can be used to screen antibodies e.g., an neutralizing assay based on monocyte derived dendritic cells, as described herein.
- Direct measurements of bovine immunoglobulin in illeal fluid in human subjects has shown that significant amounts of immunoglobulin survive transit through the stomach and small intestine (Warny et al. Gut, 44:212-217, 1999). Methods have also been described to formulate avian immunoglobulin (IgY) for GI delivery (Kovacs-Nolan and Mine Immunol. Methods. 296: 199-209, 2005).
- The invention provides a therapeutic composition comprising anti-AAI (e.g., anti-CM3 and/or anti-0.19) antibodies suitable for delivery, preferably oral delivery, to a patient in need thereof, preferably a human patient. The pharmaceutical composition may further comprise suitable carriers, adjuvants and other physiologically acceptable excipients.
- The invention also features a therapeutic composition containing antibodies with specificity for both the CM3 of SEQ ID NO:1 (or proteins substantially identical to the protein of SEQ ID NO:1) and/or the 0.19 of SEQ ID NO:2 (or proteins substantially identical to the protein of SEQ ID NO:2) as well as additional CM3- or 0.19-related proteins (e.g., CM3 or 0.19 analogs expressed in other species of cereals or other AAI proteins as disclosed herein). Such antibodies can be identified by testing specificity to all of the desired CM3- or 0.19-related proteins.
- Furthermore, the invention also features pharmaceutical compositions containing a plurality of antibodies, where different antibodies in the composition are specific for different analogs of AAI (e.g., CM3 and/or 0.19). Additionally or alternatively, such compositions can contain antibodies against both AAI (e.g., CM3 and/or 0.19), as well as gluten (e.g., gliadin and glutenin fractions, see, e.g., WO 2007/056301, which is herein incorporated by reference in its entirety). Such pharmaceutical compositions can be achieved by mixing more than one source of antibodies, or, e.g., inoculating an antibody producing animal with more than one AAI (e.g., a cow can be inoculated with variants of CM3 and/or 0.19 with adjuvants as described above thereby creating a mixture of polyclonal antibodies with differing specificities).
- The oral formulations can comprise enteric coatings, so that the active agent is delivered to the intestinal tract. Enteric formulations are often used to protect an active ingredient from the strongly acid contents of the stomach. Such formulations are created by coating a solid dosage form with a film of a polymer that is insoluble in acid environments and soluble in basic environments. Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate, methacrylate copolymers and cellulose acetate phthalate.
- The pharmaceutical compositions can be administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
- Neutralizing antibodies can be administered to a patient prior to, or concurrently, or after the ingestion of a substance that may contain an AAI (e.g., CM3 and/or 0.19). The neutralizing antibodies of the invention can also be administered to the patient on a regular dosing schedule (e.g., one, two, three times a day, or more). The neutralizing antibodies can also be administered at a specific time of day, e.g., prior to sleep or upon wakening.
- Detection and measurement of indicators of efficacy may be measured by a number of available diagnostic tools, including but not limited to, for example, by physical examination including blood tests, biopsies of the small intestine, pulmonary function tests, and chest X-rays; CT scan; bronchoscopy; bronchoalveolar lavage; lung biopsy and CT scan. Suppression of the innate immunity can be measured, e.g., by quantifying the release of cytokines at the sites of lesions. Also, both the physician and patient can identify a reduction in symptoms of a disease.
- The pharmaceutical compositions of this invention comprise any of the compounds of the present invention, or pharmaceutically acceptable derivatives thereof, together with any pharmaceutically acceptable carrier.
- The dosage and dose rate of the compounds of this invention effective to produce the desired effects will depend on a variety of factors, such as the nature of the antibody, the size of the subject, the goal of the treatment, the nature of the pathology to be treated, the specific pharmaceutical composition used, and the judgment of the treating physician. Dosage levels of between about 0.1 and about 1000 mg/kg body weight per dose, preferably between about 1 and about 500 mg/kg body weight per dose of the active ingredient antibody are useful. The antibodies of the invention can also be administered at a dose ranging between about 1 mg/kg body weight/dose and about 200 mg/kg body weight/dose, and between about 5 mg/kg body weight/dose and about 50 mg/kg body weight/dose.
- The invention features assays for detecting AAI (e.g., CM3 and/or 0.19) in food products. The assays can contain, e.g., antibodies as described above. Such antibodies can be antibodies specific for AAI proteins (e.g., CM3 and/or 0.19), and can have neutralizing or non-neutralizing activities. Such antibodies can be detectably labeled to facilitate detection. Assays for detecting proteins in a sample (e.g., a food product) are known in the art (e.g., ELISA or RIA assays). Such assays can be readily adapted to detection of AAI (e.g., CM3 and/or 0.19).
- The invention also features assays for detecting antibodies against AAI (e.g., CM3 or 0.19) in a patient sample (e.g., using an ELISA assay as described above). Such assays can be used, e.g., to diagnose a patient as being sensitive to AAI (e.g., sensitive to CM3 and/or 0.19, and as having celiac disease, ulcerative colitis, Crohn's disease, or irritable bowel syndrome). The patient sample can be any sample likely to contain antibodies against AAI (e.g., a blood sample or stool sample). The presence or heightened levels of endogenously generated antibodies against AAI can be indicative of a subject as being sensitive to AAI containing food products.
- The invention also features food products with decreased levels of AAI (e.g., CM3 and/or 0.19). Such food products can be prepared, e.g., by degrading or removing AAI prior to consumption. Such food products can also be prepared from transgenic cereals (e.g., wheat) containing nucleic acid constructs encoding RNAi molecules against AAI.
- Decreased levels of AAI (e.g., CM3 and/or 0.19) protein can be achieved, e.g., through disulfide reduction of AAI. This can be achieved by agents such dithioerithrol, or preferably by a NADP-thioredoxin system as described by Farid et al. (J Agricult Food Chem 56:7146-7150, 2008) for the improvement of digestability of soy flour. The latter and related methodologies have the advantage that disulfide reduction is non-toxic. The reduced AAIs are then easily degraded by gastric and duodenal proteases, leading to their “detoxification,” i.e., inability to elicit an innate immune response. To secure complete degradation before ingestion, the reduced AAIs can be predigested with common proteases such as pepsin, trypsin, or chymotrypsin, or with specialized enzyme preparations.
- Decreased levels of AAI (e.g., CM3 and/or 0.19) can also be achieved by separating AAI from the food product by, e.g., exposing the food product to antibodies specific for AAI. Such antibodies can be used, e.g., in a purification column to remove AAI from a solution containing AAI.
- Methods for silencing gene expression in plants is well understood in the art. The current invention features RNAi molecules specific for an AAI (e.g., against a nucleic acid sequence corresponding to the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2). Such RNAi molecules can be expressed from a nucleic acid construct introduced into a plant cell. Desirably, expression of the RNAi construct would result in a decrease of CM3 and/or 0.19 expression in the food product of 50%, 60%, 70%, 80%, 90%, 95%, 99%, or greater.
- In a specific embodiment, virus induced gene silencing (VIGS) can be used to decrease CM3 (or other AAIs) expression in, e.g., wheat or other cereals. In this embodiment, a plant virus (e.g., barley stripe mosaic virus) is engineered to contain a sequence with substantial identity to a the genomic nucleic acid sequence corresponding to CM3 (or other AAIs). This technology is reviewed, e.g., in Cakir et al. (Crop Sci. 50:S-1-S-8, 2010), which is hereby incorporated by reference in its entirety.
- To examine how far gliadin elicits innate immune responses, we stimulated the human monocytic cell lines THP-1 and U937 with different concentrations of gliadin digested with pepsin and trypsin (PT gliadin) and measured secretion of proinflammatory cytokines in the supernatant. A digest of zein, partly homolgous storage proteins from corn that lack toxicity for patients with celiac disease, served as negative control. In accordance with other studies, only PT gliadin but not PT zein caused a dose dependent stimulation of IL-8, TNF-α, and MCP-1 secretion in both cell lines (
FIG. 1 ). To rule out LPS contamination as trigger of innate responses, gliadin, LPS, and TNF-α were digested with proteinase K, completely digesting and abrogating all peptide-related activities. As expected, TNF-α lost its stimulatory capacity, while LPS was still able to induce IL-8. Importantly, PT gliadin was equally inactivated (FIG. 1 ), indicating that the stimulatory effects of gliadin were due to protein and not LPS contamination. Moreover, while IL-8 expression was comparable, human monocyte-derived dendritic cells (DC) stimulated with PT gliadin expressed TNF-α and RANTES to a much lesser extent than the LPS stimulated control (FIG. 8 ). - It was shown previously that the a-gliadin peptide p31-43 increases IL-15 secretion in celiac biopsies. However, this peptide did not elicit secretion of IL-8, TNF-α, or MCP-1 in our monocytic or intestinal epithelial cell lines (HT29, Caco-2 and T84), even at 40 μg/ml (
FIG. 1 ). This suggested the presence of other potent peptide stimulators of innate immune responses in PT gliadin. - We then analyzed human DC derived from peripheral blood monocytes of celiac patients on gluten free diet (gfd, n=8), on regular diet (n=3) and healthy controls (n=10). Although there were considerable inter-individual variations, all cells strongly reacted to gliadin stimulation by IL-8 secretion. Of note, there were no significant differences in sensitivity towards PT gliadin between celiac patients on or off gluten free diet and healthy controls, confirming recent data that demonstrated comparable activation of PT gliadin-stimulated DC from controls and CD patients. Again, PT zein had no effect on cytokine production (
FIGS. 2A-2D ). - When exposed to PT gliadin and LPS, DC also up-regulated the cell surface maturation markers CD25, CD80, CD83, and CD86 while zein showed no effect (
FIG. 2E ). - A recent study suggested that gliadin may signal via MyD88, a key adapter molecule in the toll-like receptor (TLR)/IL-10 pathway. Since MyD88 transmits signals from several TLRs, we studied peritoneal macrophages of C3H/HeJ mice that lack TLR4 responses due to a spontaneous point mutation in the TLR4 gene. In these mice KC (IL-8) and TNF-α secretion was reduced to baseline levels after gliadin or LPS stimulation compared to syngenic C3H/HeOuJ TLR4 competent mice. In macrophages from both mouse strains the specific TLR2 agonist Pam3CSK4 induced equally high amounts of KC and TNF-α, verifying otherwise intact MyD88 and TLR signaling and viability of the cells (
FIGS. 3A-3D ). - To confirm a key role of TLR4 in the innate immune response to gliadin extract, we used HEK-293 cells (that do not express TLR4 or TLR2) that were transfected with the human TLR4-CD14-MD2-complex. While non-transfected HEK-293 cells responded neither to gliadin nor to LPS stimulation, both stimulants induced an increase of IL-8 secretion in the transfected cells. Specificity of the transfection was demonstrated by the absence of IL-8 induction by the TLR2 agonist Pam3CSK4 (
FIG. 3 ). - In order to examine whether gliadin also engages TLR4 in human dendritic cells, we preincubated monocyte derived DC with anti-TLR4 and CD14 blocking antibodies before adding the stimulants. This significantly reduced IL-8 production in DC stimulated with gliadin and LPS but not with the TLR2 and TLR3 agonists Pam3CSK4 and Poly-I:C, respectively, both in DC from healthy controls (
FIG. 3E ) and from celiac disease patients. - TLR4 is unique in its ability to mediate cellular activation via two pathways: the adapter molecule MyD88 or via interferon regulatory factor 3 (IRF3) pathway. Compared to C57BL/6J wildtype mice, peritoneal macrophages from MyD88 knockout mice displayed markedly reduced KC and TNF-α secretion after gliadin and LPS stimulation, indicating a major involvement of the MyD88 pathway. Since TLR3 does not use MyD88 as adapter protein for signaling, we used the TLR3 agonist Poly I:C as positive control (
FIG. 4A ). - To analyze potential activation of the alternate pathway, we measured the secretion of RANTES in supernatants of macrophages from C57BL/6J wildtype mice. RANTES secretion was increased, suggesting that both the MyD88 dependant and independent pathway are activated by the gliadin extract (
FIG. 4B ). Taken together, we can conclude that gliadin-induced signaling is mediated via TLR4, MyD88, and TRIF, and is CD14 dependent. - We then proceeded to further define the gliadin fractions that harbored the stimulatory activity. Gliadins from the pure wheat strain “Rektor” were separated into their α-, γ- and ω-fractions via HPLC. The α-, γ-, ω1-2-, and ω5-gliadins, as well as whole gliadin were digested with pepsin and trypsin and first tested on THP-1 monocytic cells. Neither the α- nor the γ-gliadins which represent more than 90% of total gliadin harbored stimulatory activity, whereas IL-8 release was induced strongly by PT-digested ω1-2- and ω5-gliadins (
FIG. 4C ). The lack of stimulation by α- or γ-gliadin was not due to toxic by-products, since addition of LPS or whole PT gliadin fully restored stimulatory capacity (FIG. 4C ). As shown for whole PT gliadin, ω1-2- and ω5-gliadin strongly induced IL-8 secretion in TLR4 transfected HEK-293 but not in untransfected HEK-293 cells (FIGS. 4D and 4E ). - Next, we used synthetic overlapping 20 mers of the ω5 gliadin chain to identify the TLR4-stimulating peptide sequence using TLR4-CD14-MD2-transfected HEK cells and IL-8 secretion for a readout. Surprisingly, none of the synthetic peptides triggered IL-8 secretion (
FIG. 4F ). This negative finding could have been due to posttranslational modifications of the gliadin or due to a particular secondary structure that might not have been captured by the synthetic peptides. However, since most gliadins are not significantly modified posttranslationally and since their secondary structure is well reflected even by smaller peptides, we searched for other wheat proteins that might have co-purified with the ω gliadins. In comassie staining, one minor protein band with a molecular mass of 15 kD clearly distinguished the ω- from the non-reactive α- and γ-gliadin fractions. When analyzed by mass spectrometry, it could be tentatively characterized as wheat alpha amylase inhibitor CM3 and/or 0.19. As part of the albumin fraction, wheat alpha amylase inhibitors (AAIs) are highly disulfide-linked and water soluble proteins. It has been shown that they partly co-purify with gliadin and glutenin preparations. Notably, the fraction of the omega-gliadins appears to contain much of the low molecular weight albumins that contain AAIs. Thus a water-soluble gliadin fraction showed the same properties as the PT (omega) gliadins but with an even higher stimulatory capacity than PT gliadin (FIG. 5E ) and SDS-PAGE demonstrated a more prominent band with a molecular weight of 15 kD which again was confirmed as AAI by mass spectrometry. - Subsequently, we used AAI purified from wheat seed to stimulate human monocyte derived dendritic cells. HPLC analysis of this preparation showed one major peak confirming its purity. Both untreated and PT-digested AAI induced increased IL-8 secretion (
FIG. 5 ), while proteinase K digestion abrogated its stimulatory capacity, ruling out LPS contamination (FIGS. 5D and 5E ). AAI was then incubated with peritoneal macrophages from MyD88−/− and C57BL/6J wildtype mice, showing a lack of KC secretion in MyD88−/− compared to wild type cells. Moreover, AAI induced upregulation of IL-8 secretion in TLR4/MD2/CD14 transfected HEK-293 as compared to untransfected cells (FIGS. 5D-5F ), and incubation of human monocyte derived DC with blocking TLR4 and CD14 antibodies prior to addition of ATI reduced IL-8 secretion (FIG. 6C ). Overall, these results confirmed the signaling pathways previously identified with crude or ω-gliadin and demonstrated that it was indeed AAI that mediated the innate immune responses. - To examine whether the in vitro responses translated into physiologically relevant in vivo responses, we used water-soluble gliadin (which was available in larger quantities) in most experiments and AAI for select studies. When injected intraperitoneally, water-soluble gliadin lead to an increase in peripheral KC and TNF-α levels comparable to LPS, whereas water-soluble zein did not induce a response. No responses were found in MyD88−/− mice, neither with LPS nor with water-soluble gliadin (
FIG. 6A ). A recent study implicated the adaptive immune system in modulating the innate immune response. We therefore injected water-soluble gliadin into T and B cell deficient Rag1−/− mice. Rag1−/− mice showed cytokine levels similar to the ones elicited in C57BL/6J mice, indicating that the innate response was largely independent of adaptive immunity (FIG. 6B ). - Next we analyzed local intestinal effects of orally ingested ATI. To this end C57BL/6J mice were gavaged with LPS, water-soluble gliadin, or PBS, followed by measurement of transcript levels of inflammatory cytokines in the proximal duodenum. Only with water-soluble gliadin did we detect a significant upregulation of duodenal KC, MCP-1, and IL-1β (but not TNF-α) transcripts (
FIG. 6D ). Of note, LPS did not increase any of these cytokines, which is likely due to its inactivation by low pH in the stomach or by intestinal alkaline phosphatase during intestinal passage. When the same experiment was performed in TLR4 deficient C3H/HeJ mice and the corresponding wild type mice, an increase in duodenal KC transcripts was only observed in the wild type mice. Since water-soluble zein did not induce cytokine transcripts, an unspecific reaction to uncommon nutritional antigens could be ruled out (FIG. 6E ). - Experiments were also performed with purified alpha amylase inhibitor, in order to confirm this protein antigen as trigger of wheat-induced innate immune response. When we gavaged C57BL/6 mice with LPS, AAI, and water-soluble zein, AAI was indeed able to increase transcript levels of KC, IL-1β, and IL-6 but not TNF-α in the duodenal mucosa (
FIG. 6F ). While initially the observed effects appeared less significant when purified AAI was used instead of water-soluble gliadin, this can be explained by the much lower AAI concentrations used in these experiments (0.075 mg of purified protein vs. 2 mg of gliadin extract per g mouse weight). - AAI CM3 and 0.19 were recombinantly expressed in eukaryotic HEK 293 cells, in order to exclude bacterial contaminants, to ensure correct folding, and to identify which of both molecules was the active compound. The affinity purified proteins were used to stimulate monocyte derived DCs. Here, CM3, and to a lesser degree 0.19, upregulated IL-8 secretion, suggesting that CM3 as well as 0.19 AAI were the active compound (
FIG. 7 ). - CM3 and 0.19, the main ATI family members, were detected by mass spectrometry and were recombinantly expressed in eukaryotic HEK-293 cells to prevent bacterial contaminants (LPS) and to ensure correct protein folding (
FIGS. 9A and B). Both affinity purified ATIs stimulated TLR4/MD2/CD14-transfected but not untransfected HEK-293 cells confirming their TLR4-stimulating activity. In line with eukaryotic expression, the stimulatory activity of recombinant CM3 and 0.19 was maintained after additional purification using an endotoxin depletion column (FIG. 9C ). In addition, overexpression of both CM3 and 0.19 in TLR4/MD2/CD14 expressing HEK-293 cells strongly induced the canonical and the alternative TLR4-pathway (FIG. 9D ). Sequence comparison revealed that despite significant differences in primary sequence, both CM3 and 0.19 showed 5 stretches of highly conserved amino acid residues clustered around cysteins, indicative of a similar secondary structure of both ATIs (FIG. 10A ). Other ATI variants (i.e., AAIs) that occur in wheat or barley showed similar homology, suggestive of comparable biological activity (FIG. 10B ). - Purified cell culture tested LPS (E coli 055:B5) and in wheat alpha-amylase inhibitor (AAI) type I were purchased from Sigma-Aldrich (St Louis, Mo.), the TLR2 agonist N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine ×3 HCl (Pam3CSK4) and the TLR3 agonist Polyinosine-polycytidylic acid (poly-I:C)) were obtained from Invivogen (San Diego, Calif.). Other reagents were of the highest purity available and, if not mentioned otherwise, obtained from Sigma-Aldrich.
- Isolation of Gliadin Fractions and PT-Gliadin
- Unless otherwise stated gliadin purchased from Sigma-Aldrich (G3375) was used for experiments. Gliadin from the pure wheat strain ‘Rektor’ was subfractionated as described in the art. Briefly, α, γ, ω1.2 and ω5 gliadins were obtained by HPLC purification on a Nucleosil C8 column (4.6×240 mm) at 50° C., using 0.1% trifluoroacetic acid as phase A, and 99.9% acetonitrile plus 0.1% trifluoroacetic acid as phase B, and a gradient from 24% B to 56% B in 30 min. Detection was at 210 nm. Purity of the fractions was confirmed by SDS PAGE, aminoterminal sequence analysis and their characteristic amino acid composition.
- Pepsin-trypsin-digested (PT-) gliadin was generated as originally described with minor modifications. Briefly, gliadin was digested with pepsin in 0.1M HCL (pH 1.8) at 37° C. for 4 hrs, followed by pH adjustment to 7.8 and digestion with trypsin at 37° C. for 4 hrs (substrate:enzyme ratio of 1:200 for both reactions). Adjustment of the pH to 4.5 resulted in a precipitate which was removed by centrifugation at 2,500 rpm, and N-tosyl-chloromethyl-ketone was added to inhibit residual trypsin activity. The supernatant containing the PT-gliadin was dialyzed against 10 mM ammonium carbonate, pH 7.8 (molecular weight exclusion 1000D, Spectra/Por®, Serva, Heidelberg, Germany), sterile-filtered and lyophilized. A parallel digest of zein from corn (Sigma-Aldrich) was used as negative control.
- The water soluble fraction of gliadin was obtained by incubating 10 g of gliadin in 50 ml sterile water at 37° C. for 8 hrs under continuous stirring. Insolubles were removed by centrifugation and the supernatant was sterile filtered and lyophilized.
- Synthetic Peptides
- Peptide p31-43 of α-gliadin (sequence LGQQQPFPPQQPY (SEQ ID NO:3 and a scrambled control peptide (sequence GLQPFQQPQPPQY (SEQ ID NO:4)) were synthesized by AnaSpec Inc. (San Jose, Calif.). Purity of the peptides was >80% according to HPLC and mass spectrometry analysis. Forty-three 20 mer peptides with an overlap of ten amino acids covering the 440
residue omega 5 gliadin were synthesized at 60-80% purity by Primm Biotechnology (Cambridge, Mass.). - Cell Culture and In Vitro Stimulation Experiments
- THP-1, U937, HEK-293 (all from ATCC, Manassas, Va.), and HEK-293 cells stably transfected with the TLR4-CD14-MD2 complex (Invivogen) were cultured in complete RPMI or DMEM (Cellgro, Manassas, Va.) supplemented with penicillin/streptomycin and 10% fetal calf serum at 37° C. in a 5% CO2 atmosphere.
- For isolation of
peripheral monocytes 40 ml blood was obtained from 11 patients with celiac disease during their diagnostic workup (median 37 years, range 18-59 years), after prior informed consent. Eight patients were on gluten free diet and in clinical remission, three patients were newly diagnosed and therefore on a regular gluten containing diet. Control monocytes were from the buffy coat of leukopheresis concentrates of anonymous blood donors. Whole EDTA blood or leukapheresis concentrates were subjected to density gradient centrifugation over Ficoll-Hypaque (GE Healthcare, Pittsburgh, Pa.) and CD 14-positive monocytes purified by MACS separation according to the manufacturer's protocol (Miltenyi, Bergisch Gladbach, Germany). For generation of dendritic cells, monocytes were cultered in RPMI supplemented with 10% fetal calf serum, 200 U/ml rhIL-4 and 300 U/ml rhGM-CSF (both from PeproTech, Rocky Hill, N.J.) for 6-8 days. - Murine resident peritoneal macrophages were isolated by peritoneal lavage using a 3 ml syringe and 18 G needles. Three 3 ml of sterile PBS was injected into the peritoneal cavity and reaspirated after gentle massage of the abdomen. For further purification MACS separation for CD11b positive cells was done according to the manufacturer's protocol (Miltenyi).
- For stimulation cells were seeded on polystyrene wells at a density of 1×106/ml. Unless otherwise stated supernatants were harvested after a 16 hr incubation with various stimulants.
- Exclusion of LPS Contamination
- To prove that stimulatory effects were due to protein, PT-gliadin, the wheat ATI, LPS, or TNFα were incubated with or without 20 μg/ml proteinase K (Promega, Madison, Wis.) for 4 hrs at 56° C. After proteinase K inactivation by boiling for 5 minsute the digests were used for cell stimulation.
- Animals
- C3H/HeJ, C3H/HeOuJ and Rag1−/− mice were obtained from The Jackson Laboratory (Bar Harbour, Me.). The MyD88−/− mice were a kind gift from S. Akira, (Osaka University, Osaka, Japan). Congenic C57BL/6J mice served as experimental controls and were bred under the same conditions in the same facility. All experiments were done with mice at age 5-7 weeks.
- In Vivo Experiments
- Mice were injected intraperitoneally with water-soluble gliadin, zein (500 μg/g body weight) or LPS (1 μg/g) in 200 μl PBS, or PBS alone (negative control). 2 hrs after injection, mice were euthanized by ketamine/xylazine administration and blood was drawn by intraorbital bleeding.
- For gavage experiments mice were either raised on gluten free diet (C57BL/6J and MyD88−/− mice) or put on gluten free diet for at least two weeks (C3H/HeJ, C3H/HeOuJ mice), and starved the night before the experiment. Gluten free feed was obtained from Research Diets (New Brunswick, N.J.). All stimulants were diluted in PBS. Mice were administered gliadin, zein (2 mg/g mouse weight), LPS (20 μg/g mouse weight), ATI (0.075 mg/g mouse weight) in 200 μl PBS. Mice were euthanized 4 hrs after gavage and the duodenum snap frozen in liquid nitrogen.
- Cytokine/Chemokine Assays
- The concentration of IL-8, TNF-α, MCP-1, RANTES, and mouse IL-8 (KC) in cell culture supernatants and serum samples was determined using validated ELISAs (IL-8, hTNFα: BD Pharmingen, San Jose, Calif.; MCP-1, hRANTES, mRANTES, KC: R&D Systems, (Minneapolis, Minn.; mTNFα: eBioscience, San Diego, Calif.), according to the manufacturer's protocols.
- RNA Isolation and qRTPCR
- Samples from the small intestine (0.5 cm segment, 2 cm distal to the pylorus) were collected at sacrifice and snap-frozen for further analysis. Total RNA isolation was performed using Trizol reagent (Invitrogen) according to the manufacturer's instructions. Exon-exon boundary spanning primer sequences were obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank/) and sequences are listed in Table [x]. Real-time PCR was performed using LightCycler 480 SYBR Green I mastermix (Roche, Indianapolis, Ind.) and a Roche LightCycler 480 system. Mouse GAPDH served as endogenous control. PCR was set up in triplicates and threshold cycle (Ct) values of the target genes were normalized to the endogenous control. Differential expression was calculated according to the 2-ΔΔCT method.
- Blocking Experiments
- Monocyte derived dendritic cells were seeded at a concentration of 1×106/ml in 96 well plates. Cells were pre-incubated with blocking antibodies (polyclonal rat anti-TLR4, Invivogen, 10 μg/ml), polyclonal goat anti-CD14, R&D, 20 μg/ml) for 3 hrs at 37° C. before stimulation.
- Flow Cytometry
- Human monocyte derived DC were stimulated with LPS, PT gliadin, and PT zein overnight. For flow cytometry analysis, cells were pre-incubated with FcR blocking reagent (Miltenyi) for 15 min at 4° C. before staining with monoclonal antibodies (
final concentration 10 μg/ml, all from eBioscience) for 30 min at 4° C. Cells were then washed with staining buffer (PBS, 1% BSA), cell viability was assessed by DAPI exclusion (0.1 μg/ml, Roche) and only viable cells were analyzed by flow cytometry using a 4 laser LSRII (BD Biosciences) and Flowjo software (Tree Star, Inc.). - Recombinant Expression of AAI CM3 and 0.19 Proteins
- Recombinant flag-tagged CM3 or 0.19 were generated in a eukaryotic system using the expression vector pCDNA (Invitrogen) and HEK 293 cells. cDNA was optimized and synthesized by genscript (sequence number AY436554.1) and correct orientation was checked by sequencing analysis. The expressed protein was purified from supernatant with anti-flag agarose beads in batch technique according to the manufacturer's protocol (Sigma).
- Statistical Analysis
- Differences were tested for statistical significance by the unpaired t-test. p<0.05 was considered significant. In all graphs, error bars depict standard errors of the mean.
- Recombinant Expression of ATI CM3 and 0.19 Proteins
- In order to exclude bacterial contaminants, recombinant flag-tagged ATI CM3 and 0.19 were generated in eukaryotic HEK-293 cells, using cDNAs optimized to fit eukaryotic codon usage (Genscript, Pscataway, N.J.; CM3 and 0.19 with NCBI GenBank sequence numbers AY436554.1 and AY729672.1, respectively). cDNAs were cloned into pUC57 and correct reading frames and orientations confirmed by sequence analysis and KpnI-ApaI restriction. CM3 and 0.19 open reading frames were then cloned into pcDNA3.1 (+) (Invitrogen). In order to increase expression level of ATI 0.19, the HindIII-KpnI fragment of the PCR product was fused with the Flag-tag at the N- instead of the C-terminus using the
forward primer 5′-CCCAAGCTTAGCGGACCCTGGATGTGCTAC and thereverse primer 5′-CGGGGTACCCCTCAGGCGTCAGGGTAAGCGGCCAC. The CM3 and 0.19 constructs were then subcloned into the pFLAG-CMV4 vector (Sigma-Aldrich) and the correct orientation was confirmed by sequencing with the N-terminal sequencing primer 5′-AATGTCGTAATAACCCCGCCCC-GTTGACGC. - Subconfluent HEK-293 cells cultured on 10 cm tissue culture dishes were transfected with 10 μg of plasmid DNA encoding CM3 and 0.19 using lipofectamine 2000 (Invitrogen), followed by incubation in DMEM (Mediatech) containing 1% fetal bovine serum and 100 IU penicillin/100 μg/ml streptomycin for 48 h. The media were obtained by centrifugation at 4,500 rpm for 10 min at 4° C. Cells were then washed with ice cold-PBS [pH 7.4], resuspended in buffer C (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 50 mM NaF, 1 mM Na3VO4, 1 mM EDTA, 0.5% TritonX-100, 0.5% sodium deoxycholate) supplemented with EDTA-free Complete protease inhibitors (Roche) for 15 min on ice, and then centrifuged at 14,000 rpm for 20 min at 4° C. Aliquots of the detergent-soluble and insoluble fractions were boiled at 100° C. (the pellet in SDS sample buffer), separated on a SDS-15% polyacrylamide gel, and subjected to Western blot analysis. Protein lysates were probed with rabbit anti-flag antibody (Sigma-Aldrich), followed by horseradish peroxidase-labeled anti-rabbit IgG (Vector Laboratories, Burlingame, Calif.). Protein bands were visualized using enhanced chemiluminescence (Thermo Scientific, Rockford, Ill.) and X-Oat 2000A processor (Kodak).
- Purification of α-Amylase Inhibitors, CM3 and 0.19
- While sufficient CM3 protein was secreted into the media, 0.19 ATI had to be isolated from the detergent-soluble fraction. Briefly, HEK-cells expressing 0.19 were washed with ice cold-PBS, resuspended in 50 ml of buffer C for 15 min on ice, and centrifuged at 14,000 rpm for 20 min at 4° C. Thus, the solubilized 0.19 and soluble CM3 were bound to Flag-M2 agarose (Sigma-Aldrich) pre-equilibrated with buffer C by gentle shaking for 3 h at 4° C., washed three times with buffer C, and further washed three times with buffer D (Buffer C without detergents). Bound ATIs were eluted with TBS [pH 7.4] containing Flag peptide (Sigma-Aldrich). In order to rigorously exclude endotoxin, eluted CM3 and 0.19 were also applied to an entotoxin removal column (Norgen Biotek corp., Thorold, ON, Canada). ATIs were the used at 5 μg/ml to stimulate HEK-293 cells stably transfected with the TLR4-CD14-MD2 complex, and IL-8 secretion was quantified after 24 h using the IL-8 ELISA as described above.
- Downstream Signaling Pathways Induced by CM3 and 0.19 Overexpression
- HEK-293 cells stably expressing TLR4-CD14-MD2 were induced to express CM3 or 0.19, respectively, followed by cell lysis in buffer C. Lysates were cleared by centrifugation at 14,000 rpm for 20 min at 4° C., and 50 μg of protein run on a 15% SDS-gel and subjected to Western blotting to analyze activation of the canonical and the alternative (p-IRF3) pathways using antibodies to phosphorylated and unphosphorylated (p-NF-κB/p65) and IRF3 (all from Cell Signaling Technology, Danvers, Mass.).
- Various modifications and variations of the described methods and compositions of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific desired embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the fields of medicine, immunology, pharmacology, endocrinology, or related fields are intended to be within the scope of the invention.
- All publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication was specifically and individually incorporated by reference.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/695,349 US20130266584A1 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for treating celiac disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33004310P | 2010-04-30 | 2010-04-30 | |
US41761310P | 2010-11-29 | 2010-11-29 | |
US13/695,349 US20130266584A1 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for treating celiac disease |
PCT/US2011/034516 WO2011137322A2 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for treating celiac disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/034516 A-371-Of-International WO2011137322A2 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for treating celiac disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/666,030 Continuation US11795213B2 (en) | 2010-04-30 | 2017-08-01 | Methods and compositions for treating celiac disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130266584A1 true US20130266584A1 (en) | 2013-10-10 |
Family
ID=44862131
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/695,349 Abandoned US20130266584A1 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for treating celiac disease |
US15/666,030 Active US11795213B2 (en) | 2010-04-30 | 2017-08-01 | Methods and compositions for treating celiac disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/666,030 Active US11795213B2 (en) | 2010-04-30 | 2017-08-01 | Methods and compositions for treating celiac disease |
Country Status (3)
Country | Link |
---|---|
US (2) | US20130266584A1 (en) |
EP (1) | EP2563394B1 (en) |
WO (1) | WO2011137322A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015168416A1 (en) * | 2014-05-02 | 2015-11-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, removal, or inactivation cereal amylase trypsin inhibitors in cereals, flours and complex foods |
WO2017075456A1 (en) * | 2015-10-30 | 2017-05-04 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
US11679141B2 (en) | 2019-12-20 | 2023-06-20 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
GB2619051A (en) * | 2022-05-25 | 2023-11-29 | Airbus Operations Ltd | Aircraft landing gear assembly |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017122407A1 (en) | 2017-09-27 | 2019-03-28 | Ernst Böcker Gmbh & Co. Kg | Compatible flour composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5792506A (en) * | 1991-10-12 | 1998-08-11 | The Regents Of The University Of California | Neutralization of food allergens by thioredoxin |
JP3999825B2 (en) * | 1996-01-18 | 2007-10-31 | 日清ファルマ株式会社 | Visceral fat accumulation inhibitor |
US7179964B2 (en) * | 1999-03-29 | 2007-02-20 | The Regents Of The University Of California | Transgenic plants with elevated thioredoxin levels |
US8071101B2 (en) * | 2005-11-03 | 2011-12-06 | Avaxia Biologics, Inc. | Antibody therapy for treatment of diseases associated with gluten intolerance |
-
2011
- 2011-04-29 EP EP11775619.7A patent/EP2563394B1/en active Active
- 2011-04-29 US US13/695,349 patent/US20130266584A1/en not_active Abandoned
- 2011-04-29 WO PCT/US2011/034516 patent/WO2011137322A2/en active Application Filing
-
2017
- 2017-08-01 US US15/666,030 patent/US11795213B2/en active Active
Non-Patent Citations (2)
Title |
---|
Pastorello et al. 2007. Int Arch Allergy Immunol. 144:10-22 * |
WebMD (https://www.nlm.nih.gov/medlineplus/ency/article/007447.htm, updated 2/11/14, downloaded 5/4/2016) * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015168416A1 (en) * | 2014-05-02 | 2015-11-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, removal, or inactivation cereal amylase trypsin inhibitors in cereals, flours and complex foods |
WO2017075456A1 (en) * | 2015-10-30 | 2017-05-04 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
CN108697116A (en) * | 2015-10-30 | 2018-10-23 | 贝丝以色列女执事医疗中心 | For measuring the bioactivity of the cereal starch enzyme trypsin inhibitor in cereal, flour, plant and complex food, amount, removing or the method for inactivation |
AU2016343738B2 (en) * | 2015-10-30 | 2021-05-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
US11291221B2 (en) | 2015-10-30 | 2022-04-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
US11679141B2 (en) | 2019-12-20 | 2023-06-20 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
US11744874B2 (en) | 2019-12-20 | 2023-09-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
US11896646B2 (en) | 2019-12-20 | 2024-02-13 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
GB2619051A (en) * | 2022-05-25 | 2023-11-29 | Airbus Operations Ltd | Aircraft landing gear assembly |
Also Published As
Publication number | Publication date |
---|---|
EP2563394A4 (en) | 2013-11-20 |
US11795213B2 (en) | 2023-10-24 |
WO2011137322A2 (en) | 2011-11-03 |
EP2563394A2 (en) | 2013-03-06 |
WO2011137322A3 (en) | 2011-12-15 |
EP2563394B1 (en) | 2018-03-21 |
US20180179268A1 (en) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11795213B2 (en) | Methods and compositions for treating celiac disease | |
Junker et al. | Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4 | |
US7462688B2 (en) | Peptides for diagnostic and therapeutic methods for celiac sprue | |
Huebener et al. | Specific nongluten proteins of wheat are novel target antigens in celiac disease humoral response | |
US8728471B2 (en) | Antibody therapy for treatment of diseases associated with gluten intolerance | |
CN104395345A (en) | Antibodies to matrix metalloproteinase 9 | |
KR20150058404A (en) | Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia | |
US20140363818A1 (en) | EGFR and PAR2 Regulation of Intestinal Permeability | |
ES2662871T3 (en) | Immunogenic gluten peptides and their applications | |
US20150329624A1 (en) | Igy composition for use in celiac disease | |
CA2925000A1 (en) | Compositions and methods related to oat sensitivity | |
US20130130965A1 (en) | Method to detect and treat infectious or inflammatory diarrhea based on reg1 | |
WO2014180485A2 (en) | Pappalysin regulator | |
WO2020197304A1 (en) | Composition for preventing, ameliorating, or treating pancreatic cancer, including tetraspanin-2 inhibitor as active ingredient | |
JP2010229122A (en) | Anticancer agent, medicine, and test agent to cancer disease | |
US20020081312A1 (en) | Recombinant cryptosporidium parvum antigen and detection of antibodies thereto | |
WO2019035602A9 (en) | Stomach cancer diagnosis using blood gkn1 protein | |
Gujral | Antibody-based diagnostic and therapeutic approaches on gluten-sensitive enteropathy | |
KR20220140378A (en) | Novel target for anti-cancer and immune-enhancing | |
BR102016025687A2 (en) | MONOCLONAL ANTIBODY FOR PARACOCCIDIOIDOMYCOSIS DIAGNOSIS AND USES | |
Jones | The author hereby certifies that the use of any copyrighted material in the thesis manuscript entitled | |
WO2015054210A2 (en) | T. suis excretory/secretory products and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., MASSAC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIBERMANN, TOWIA;DILLON, SIMON T.;SIGNING DATES FROM 20121218 TO 20121220;REEL/FRAME:030031/0634 |
|
AS | Assignment |
Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., MASSAC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHUPPAN, DETLEF;JUNKER, YVONNE;SIGNING DATES FROM 20130603 TO 20130604;REEL/FRAME:030625/0286 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:BETH ISRAEL DEACONESS MEDICAL CENTER;REEL/FRAME:039601/0365 Effective date: 20160805 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |